Hydroxyphenyl propionate compound for tumor immunotherapy and composition and application thereof

By identifying microbiome-derived hydroxyphenyl propionate compounds, enhancing interferon regulators and the NF-κB pathway, the problem of unclear molecular mechanisms of cancer immunology by symbiotic microorganisms was solved, and significant anti-tumor immune effects were achieved.

CN121218982APending Publication Date: 2025-12-26UTI LIMITED PARTNERSHIP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202480034060.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-22
Filing Date
2024-03-22
Publication Date
2025-12-26

AI Technical Summary

Technical Problem

In the current technology, the molecular mechanisms by which symbiotic microbiomes affect cancer immunology are not yet clear, and there is a lack of effective anti-tumor active compounds.

Method used

Through deep multi-omics sequencing analysis, a microbiome-derived hydroxyphenyl propionate (HPP) compound was identified that can bind to gasdermin D, enhance the interferon regulatory factor (IRF) and NF-κB pathways, promote cytokine secretion, and improve anti-tumor immunity.

Benefits of technology

HPP compounds significantly enhanced the aggregation of tumor-specific CD8 T cells and the release of IL-1α and IL-1β, thereby improving the anti-tumor immune response and demonstrating potential anti-cancer therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121218982A_ABST
    Figure CN121218982A_ABST
Patent Text Reader

Abstract

The present application relates to the use of hydroxyphenyl propionate compounds of formula (I), (II), (III), (IV) or (V) or pharmaceutically acceptable salts, solvates and / or ester prodrugs thereof for increasing anti-tumor immunity, to compositions comprising them, and to their use, for example, in cancer immunotherapy. More specifically, the present application relates to compounds useful in the treatment of diseases, disorders or conditions that can be treated by increasing the anti-tumor immunity of cells, such as cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Cross-references to related applications

[0001] This application claims priority to co-pending U.S. Provisional Patent Application No. 63 / 453,947, filed March 22, 2023, the entire contents of which are incorporated herein by reference. Technical Field

[0002] This application relates to hydroxyphenyl propionate compounds that can enhance antitumor immunity, compositions comprising the same, and their use in, for example, therapies. More specifically, this application relates to compounds that can be used to treat diseases, disorders, or conditions (such as cancer) by enhancing antitumor immunity. Background Technology

[0003] The microbiome has a significant impact on immune health and response to immunostimulatory therapies, including cancer immunotherapy. Cancer immune surveillance relies on dynamic, stepwise interactions between immunogenic tumors and cells of the innate and adaptive immune systems. Immunity 39, 1-10 (2013); Nature 541, 321-330 (2017)). Myeloid cells in the tumor microenvironment (TME) are central to this complex interaction because they can detect the presence of cancer cells and alert cytotoxic T cells (Cytotoxic T cells). Immunity 39, 1-10 (2013); Nature 541, 321-330 (2017)). However, myeloid cells are also typically polarized in the TME, tending towards immunosuppression and actively participating in cancer immune evasion ( ). Journal for Immunotherapy of Cancer 7, (2019); Nat. Med. 24, (2018) ). The molecular mechanisms regulating myeloid cell function in the TME are being gradually revealed, and recent studies have shown that symbiotic microorganisms and their derived metabolites play an important role in this process ( Frontiers in Immunology 6, (2015); Cell Death Differ. 26, (2019); J. Leukoc.Biol. 100, (2016); Nature Reviews Cancer 17, (2017)). This has prompted clinical evaluation of fecal transplantation as an intervention to improve cancer treatment outcomes and immunotherapy responses, with promising early results. Oncoimmunology 9, 1-8 (2020); Nat. Med. 24, (2018); Davar, D. et al. Science 371, (2021); Baruch, EN. et al. Science 371, (2021)).

[0004] An early study showed that microbiome-derived deaminotyrosine (3,4-HPP) can stimulate the amplification circuit of type 1 interferon signaling and protect the human body from the effects of influenza virus lesions. Science 357, 498-502 (2017)). Conversely, other studies have reported that specific isomers of HPP metabolites can exhibit anti-inflammatory or antioxidant properties in certain situations ( ). FASEB J. 34, 16117-16128 (2020); J. Cell. Physiol. 235, (2020); J. Agric. Food Chem. 69, (2021)). However, little is known about the molecular mechanisms by which symbiotic microorganisms influence cancer immunology. Furthermore, previous studies have not demonstrated that these compounds possess antitumor activity. Summary of the Invention

[0005] The applicant conducted in-depth multi-omics sequencing analysis on genetically identical mice containing different microbiomes to investigate the interactions between symbiotic microbes, their derived metabolites, and anticancer immunity. A microbiome-derived metabolite called hydroxyphenyl propionate (HPP) has been identified that enhances cancer immune surveillance, for example, by promoting cytokine secretion into the TME through gasdermin D (GSDMD) pores on myeloid cells.

[0006] HPP molecules bind to GSDMD and enhance the interferon regulatory factor (IRF) and NF-κB pathways in a GSDMD-independent manner. The presence of multiple molecular targets in mammals suggests that how microbiome-derived metabolites can significantly influence antitumor immunity is a complex process of natural selection. This paper has shown that accelerated GSDMD cleavage leads to enhanced IL-1α and IL-1β release and the aggregation of tumor-specific CD8 T cells. The results indicate that HPP compounds may be used to treat cancer / enhance antitumor immunity. Therefore, this application includes a method for enhancing antitumor immunity in biological samples or subject cells, comprising administering an effective amount of one or more compounds of this application to the cells, wherein the compounds of this application are selected from compounds of formula (I) or their pharmaceutically acceptable salts, solvates, and / or ester prodrugs:

[0007] in R 1 R 2 and R 3 It is OH or H independently, provided that R is present. 1 R 2 and R 3 At least one of them is OH.

[0008] In some embodiments, this application includes a method for enhancing antitumor immunity in biological samples or subject cells, comprising administering an effective amount of one or more compounds of this application to the cells, wherein the compounds of this application are selected from compounds of formulas (II), (III), and (IV) or their pharmaceutically acceptable salts, solvates, and / or ester prodrugs:

[0009] in R 4 Selected from halogens, NR 5 R 6 and C 1-3 Alkyl groups; and R 5 and R 6 Independently selected from H and C 1-3 alkyl;

[0010] in R 7 It is OH; and n is 3-5; or (IV).

[0011] In some embodiments, this application includes a method for enhancing antitumor immunity in biological samples or subject cells, comprising administering an effective amount of one or more compounds of this application to the cells, wherein the compounds of this application are selected from compounds of formula (V) or their pharmaceutically acceptable salts, solvates, and / or ester prodrugs:

[0012] in R 8 R 9 and R 10 It is OH or H independently, provided that R is present. 8 R 9 and R 10 At least one of them is OH, or R 8 R 9 and R 10 One of them is selected from halogen, NR 13 R 14 and C 1-3 Alkyl groups, and R 8 R 9 and R 10 The other two are H; R 13 and R 14Independently selected from H and C 1-3 alkyl; R 11 Selected from H and =O; R 12 Selected from H, C 1-4 Alkyl and succinimide; and p is 1-4.

[0013] This application also includes a method for enhancing anti-tumor immunity, comprising administering a therapeutically effective amount of one or more compounds of this application to a subject in need.

[0014] This application also includes a method for treating cancer in cells of a biological sample or subject in need, comprising administering an effective amount of one or more compounds of this application to the cells.

[0015] This application also includes a method of treating cancer, comprising administering a therapeutically effective amount of one or more compounds of this application to a subject in need.

[0016] This application also includes a method of treating cancer, comprising administering a therapeutically effective amount of one or more compounds of this application to a subject in need, in combination with another known agent for treating cancer or another known cancer therapy.

[0017] This application also includes a pharmaceutical composition comprising one or more compounds of this application and a pharmaceutically acceptable carrier, wherein one or more compounds of this application are present in the composition in an amount effective in increasing antitumor immunity or treating cancer.

[0018] In some embodiments, the pharmaceutical composition further includes one or more additional anticancer agents.

[0019] This application also includes a method for enhancing immune surveillance in biological sample or subject cells by increasing GSDMD lysis while partially preventing cell death, and by enhancing the NF-κB pathway by promoting the release of pro-inflammatory cytokines (e.g., IL-1α and IL-1β) in biological sample or subject cells, comprising administering an effective amount of one or more compounds of this application to the cells.

[0020] This application includes a method for enhancing anti-tumor immunity in cells (within a biological sample or within a subject) by increasing the release of tumor stroma IL-1β and the accumulation of tumor-specific CD8 T cells in the TME, comprising administering an effective amount of one or more compounds of this application to the cells.

[0021] This application also includes a method for treating a disease, disorder, or condition that can be treated by increasing GSDMD cleavage, comprising administering a therapeutically effective amount of one or more compounds of this application to a subject in need.

[0022] This application also includes a method for treating a disease, disorder, or condition that can be treated by increasing the release of tumor stroma IL-1β and the accumulation of tumor-specific CD8 T cells in the TME, comprising administering a therapeutically effective amount of one or more compounds of this application to a subject in need.

[0023] This application also includes a method for treating a disease, disorder, or condition that can be treated by increasing GSDMD cleavage, comprising administering to a subject in need a therapeutically effective amount of one or more compounds of this application, in combination with another known pharmaceutical agent that can be used to treat a disease, disorder, or condition that can be treated by accelerating GSDMD cleavage.

[0024] This application also includes a method for treating a disease, disorder, or condition that can be treated by increasing the release of tumor stromal IL-1β and the accumulation of tumor-specific CD8 T cells in the TME, comprising administering to a subject in need a therapeutically effective amount of one or more compounds of this application, in combination with another known agent that can be used to treat a disease, disorder, or condition that can be treated by increasing the release of tumor stromal IL-1β and the accumulation of tumor-specific CD8 T cells in the TME.

[0025] In some embodiments, the disease, disorder, or condition that can be treated by increasing GSDMD lysis is cancer. In some embodiments, the disease, disorder, or condition that can be treated by increasing tumor-stromal IL-1β release and the accumulation of tumor-specific CD8 T cells in the TME is cancer.

[0026] This application also includes a method for enhancing the efficacy of one or more adjunct agents and / or cancer therapies for treating cancer, comprising administering an effective amount of one or more compounds of this application to a subject in need, in combination with an effective amount of one or more adjunct agents and / or cancer therapies for treating cancer.

[0027] Other features and advantages of this application will become apparent from the following detailed description. However, it should be understood that while the detailed description and specific embodiments illustrate implementations of this application, they are given by way of example only, and the scope of the claims should not be limited by these embodiments but should be given the broadest interpretation in accordance with the entire specification. Attached Figure Description

[0028] This application will be described in more detail with reference to the accompanying drawings and tables, wherein: Figure 1 The study demonstrates the association between the host microbiome and tumor immune surveillance capabilities. ab, PcoA and relative abundance of microbiota at the cytokine level in fecal microbiome samples from female CR, TAC, or JAX C57BL / 6 mice before tumor implantation (n=5 / group, two-time combined experiments, weighted UniFrac distance, pairwise PERMANOVA test); ce, titer survival curves of M3-9-M tumor cells orally implanted from the gastrocnemius muscle of female C57BL / 6 mice derived from CR, TAC, or JAX (n=4-5 / group, single experiment); f, overall survival of M3-9-M tumor cells orally implanted from female CR, TAC, and JAX C57BL / 6 mice (n=10-13 / group, two-time combined experiments, Log-Rank test); g, CD8 T cell depletion using anti-CD8 (clone 2.43) neutralizing antibody against orally implanted JAX... The effect of ABX supplementation on the overall survival of M3-9-M tumors in female C57BL / 6 mice (n=4 / group, single experiment); h, flow cytometry analysis of CD8 T cell frequency in M3-9-M tumor masses 18 days after orthotopic implantation (n=5 / group, two-combination experiment, unpaired t-test); i, fecal microbial DNA analysis of mice receiving drinking water supplemented with or without ABX for two weeks. 16S The qPCR cycle number of the gene (n=6 / group, two-combination experiments, unpaired t-test); j, body weight of mice receiving drinking water supplemented with or without ABX (n=5 / group, two-combination experiments); k, overall survival of M3-9-M tumors orally implanted in female CRC57BL / 6 mice receiving normal or ABX-supplemented drinking water (n=8-12 / group, two-combination experiments, Log-Rank test); l, overall survival of M3-9-M tumors orally implanted in female JAX C57BL / 6 mice receiving normal or ABX-supplemented drinking water (n=11-12 / group, two-combination experiments, Log-Rank test).

[0029] Figure 2This demonstrates that different microbiomes in genetically identical hosts produce different tumor immune surveillance capabilities. a, Production steps of IMDM mice; bd, PcoA of fecal microbiomes at the end of each production step of IMDM mice (dots represent each mouse, PERMANOVA test, weighted UniFrac method); e, PcoA of fecal microbiomes of 6-8 week old IMDM-CR and IMDM-JAX mice, combined from 3 litters and 3 generations (dots represent each mouse, PERMANOVA test, weighted UniFrac method); fg, Relative abundance of fecal bacteria in IMDM mice, identified by 16S amplicon sequencing; h, In, Workflow. ij, Growth kinetics and overall survival of M3-9-M tumors growing in female IMDM-CR and IMDM-JAX mice (n=10-12 / group, two-way combined experiment, two-way ANOVA for growth kinetics, Log-Rank test for overall survival); kl, Growth kinetics and overall survival of M3-9-M tumors growing in male IMDM-CR and IMDM-JAX mice (n=7 / group, two-way combined experiment, two-way ANOVA for growth kinetics, Log-Rank test for overall survival); mn, M3-9-M tumors growing in male IMDM-CR and IMDM-JAX mice. OVA Tumor growth kinetics and overall survival (n=12-25 / group, two-stage combined experiments, two-way ANOVA for growth kinetics, Log-Rank test for overall survival); o, flow cytometry detection of M3-9-M tumors grown for 18 days. OVA OVA-specific CD8 T cells in tumors (n=6 / group, two combined experiments, unpaired t test).

[0030] Figure 3 This study demonstrates how different microbiomes lead to unique metabolomics signatures within genetically identical hosts, and how specific classes of metabolites are associated with enhanced tumor immune surveillance capabilities in the host. ab, PC plots and Spearman correlation heatmaps of fecal metabolomics in male IMDM-CR and IMDM-JAX mice (samples pooled from two different experiments; ellipses represent 95% confidence intervals); cd, M3-9-M implanted orally in male IMDM-CR and IMDM-JAX mice. OVAPC plots and Spearman correlation heatmaps of tumor metabolomics (samples collected from two different experiments, ellipses plotting 95% confidence intervals); ef, PC plots and Spearman correlation heatmaps of fecal metabolomics in female IMDM-JAX mice receiving normal or ABX-supplemented water (samples collected from two different experiments, ellipses plotting 95% confidence intervals); gh, PC plots and Spearman correlation heatmaps of M3-9-M tumor metabolomics implanted in situ in female IMDM-JAX mice receiving normal or ABX-supplemented water (samples collected from two different experiments, ellipses plotting 95% confidence intervals); ij, volcano plots of fecal and tumor metabolites from male IMDM-CR and IMDM-JAX mice, respectively (samples collected from two different experiments, ellipses plotting 95% confidence intervals); kn, fecal and M3-9-M metabolomics from male IMDM-CR and IMDM-JAX mice. OVA Relative levels of selected metabolites in tumors (samples pooled from two different experiments, unpaired t-test). The same metabolomics dataset was used to generate different types of charts for the same experimental groups.

[0031] Figure 4This study demonstrates how different microbiomes lead to unique metabolomics signatures within genetically identical hosts, and the identification of metabolites associated with tumor immune surveillance capabilities. ab, PC scores and Spearman correlation heatmaps of fecal metabolomics in female IMDM-CR and IMDM-JAX mice (samples from two different experiments, ellipses plotting 95% confidence intervals); cd, PC scores and Spearman correlation heatmaps of orthotopic M3-9-M RMS metabolomics implanted in female IMDM-CR and IMDM-JAX mice (samples from two different experiments, ellipses plotting 95% confidence intervals); ef, fecal and tumor metabolites of female IMDM-CR and IMDM-JAX mice screened by volcano plot, with fold change threshold (x)² and t-test threshold (y) of 0.05 (samples from two different experiments, adjusted by FDR, logarithmically transformed p-values); gh, fecal and M3-9-M metabolites of female IMDM-CR and IMDM-JAX mice. Relative levels of L-gln metabolites in RMS tumors (samples pooled from two different experiments, unpaired t-test); ij; relative levels of HPP metabolites in feces of female IMDM-CR and IMDM-JAX mice and M3-9-M RMS (samples pooled from two different experiments, unpaired t-test); kl, relative levels of HPP metabolites in feces of female IMDM-JAX mice receiving normal or supplemented water with ABX and M3-9-M RMS tumors (samples pooled from two different experiments, unpaired t-test). The same metabolomics dataset was used to generate different types of graphs for the same experimental groups.

[0032] Figure 5 The determination of HPP metabolite treatment strategies is illustrated. a, Structure of exemplary HPP isomers; b, Workflow of cd; c, Overall survival after treatment with different doses of intraperitoneal 3,2-HPP (single experiment); d, Changes in mouse body weight after treatment with different doses of intraperitoneal 3,2-HPP (single experiment); e, Workflow of f; f, Serum levels of 3,2-HPP metabolites at different time points after intraperitoneal delivery of 83 mg / kg mouse body weight of 3,2-HPP (single experiment); g, Workflow of h; h, Changes in mouse body weight after treatment with different metabolites (single experiment); i, Workflow of jk; jk, B16.F10 and M3-9-M in IMDM-CR mice treated with solvent or 3,2-HPP 7 days after tumor implantation. OVAOverall survival rate (two-combination experiments, Log-Rank test); l, mp workflow; mp, flow cytometry measurement of the effectiveness of anti-CD8 neutralizing antibody (clone 2.43; ip) in mice, m, solvent, n, 3,2-HPP treatment, o, anti-CD8 antibody treatment, p, anti-CD8 antibody + 3,2-HPP treatment.

[0033] Figure 6 This illustrates the exemplary microbiome-derived metabolite 3,2-HPP enhancing antitumor immunity. The workflow of a, be; be, M3-9-M in female IMDM-CR mice and M3-9-M in male IMDM-CR mice after receiving metabolite ip treatment starting from day 1. OVA Overall survival curves of tumor immune surveillance in female IMDM-CR mice (B16.F10) and male IMDM-CR mice (M3-9-M) (two-stage combined experiments, Log-Rank test); workflows for f and gh; the effect of gh and ABX on the overall survival curves of tumor immune surveillance in female IMDM-JAX and IMDM-CR mice treated with 3,2-HPP ip (two-stage combined experiments, Log-Rank test); workflows for i and jk; flow cytometry detection of M3-9-M in male IMDM-CR mice treated with 3,2-HPP 18 days after tumor implantation. OVA Expression of OVA-specific CD8 T cells and exhaustion markers in this cell type in the TME (two-stage combined experiment, unpaired t-test); workflow of l, m; effect of m, CD8 T cells on the overall survival curve of immune surveillance in M3-9-M female IMDM-CR mice treated with 3,2-HPPi.p. (Log-Rank test, single experiment); workflow of n, op; effect of op, anti-PD-1 and anti-PD-L1 therapy on the overall survival curve of immune surveillance in M3-9-M and B16.F10 female IMDM-CR mice treated with 3,2-HPPi.p., respectively (two-stage combined experiment, Log-Rank test).

[0034] Figure 7 Exemplary HPP-enhanced TME cancer immune signaling pathways are illustrated: a, an animal experimental workflow for scRNA-seq; b, through the manipulation of M3-9-M from orthotopic implantation. OVAc) Immune cell types in mouse TME identified by scRNA-seq of CD45+ cells isolated from RMS; d) Number of cells used for statistical analysis of scRNA-seq experiments; e) Number of significantly affected genes obtained by paired comparison (Wilcoxon rank-sum test); f) Distribution map of all significantly affected genes obtained by paired comparison, these genes overlap through the same or shared pathways; g) Bar graph of transcription regulators of genes affected by 3,2-HPP treatment; gh) Mouse RAW-Dual cells treated with LPS and VSV in the presence of HPP metabolites. TM Induction of NF-κB and IRF in cells (triple combination experiment, one-way ANOVA test); i,jl workflow of animal experiments used;jl, showing M3-9-M and M3-9-M in male IMDM-CR mice treated with HPP metabolites ip from day 1. OVA The overall survival curves of B16.F10 immune surveillance in female IMDM-CR mice (two combined experiments, Log-Rank test).

[0035] Figure 8 The effects of exemplary 3,2-HPP metabolite treatment on gene expression in different immune cell subsets within the TME are shown. (af) A genus map (Wilcox rank-sum test) of overlapping genes that were statistically significantly affected in paired comparisons of IMDM-CR versus IMDM-JAX and IMDM-CR versus IMDM-CR-HPP is shown.

[0036] Figure 9 Exemplary HPP isoforms (I-1, I-2, and I-3) are shown to enhance NF-κB and IRF signaling pathways in myeloid cells. a) THP1-Dual cells were treated with LPS for 0 to 24 hours in the presence of solvent or HPP metabolites. TM Cellular NF-κB pathway induction (two-stage combined experiment); bf, THP1-Dual NF-κB pathway inducer treatment for 16 hours in the presence or absence of HPP isoforms. TM Cells (three-way combination experiment, one-way ANOVA test); gm, THP1-Dual™ cells treated with different IRF pathway inducers for 16 hours in the presence or absence of HPP isoforms (three-way combination experiment, one-way ANOVA test); no, THP1-Dual™ cells treated with LPS-induced NF-κB and VSV-induced IRF pathways for 16 hours in the presence or absence of L-gln (three-way combination experiment).

[0037] Figure 10Exemplary HPP isoforms (I-1, I-2, and I-3) are shown to enhance NF-κB signaling and antitumor immunity by binding to GSDMD. a) Human THP1-Dual cells treated with LPS and HPP molecules for 16 hours. TM Reporting NF-κB induction in cells (six-combination experiments, one-way ANOVA test); b, identifying THP1-Dual cells by performing TPP technology. TM Potential HPP targets in cells (two-stage combined experiments, proteome coverage: 4301, NPARC test); c, protein-protein interaction network between HPP target hits (red) and transcription regulators of genes affected by 3,2-HPP treatment (yellow); d, GSDMD protein denaturation curves affected by 3,2-HPP treatment (two-stage combined experiments, NPARC test); e, workflow of fg; fg, M3-9-M from male WT and GSDMD-KO mice orally implanted with solvent or 3,2-HPP metabolites. OVA Tumor growth kinetics and overall survival in RMS (n=8 / group; two combined experiments, two-way ANOVA for growth kinetics, Log-Rank test for overall survival); h, HEK-Blue TM Response of IL-1β cells (which induce NF-κB / AP-1 via IL-1 receptor signaling) to LPS and HPP molecule-treated supernatants of THP1-WT and THP1-GSDMD-KO cells (triple-combination experiment, one-way ANOVA test); i, HEK-Blue TM The reaction of IL-1β cells to supernatants of THP1-WT and THP1-GSDMD-KO cells treated with LPS and HPP molecules for 3 hours followed by NG (triple-combination experiments, one-way ANOVA test); j, Western blots of THP-1 cells treated under different conditions (representative results from two experiments); k, quantification of GSDMD peptides from publicly available proteomic profiles of stage IV melanoma patients undergoing anti-PD-1 therapy (R, n = 40 and NR, n = 27); lm, detection of huPBMC supernatants treated with LPS and HPP molecules for 3 hours followed by NG: l, HEK-Blue TM IL-1β cellular response (triple-combination experiment, one-way ANOVA test); m, released LDH level (triple-combination experiment, one-way ANOVA test).

[0038] Figure 11 The expression of genes involved in the inflammasome pathway, identified by scRNAseq, is shown.

[0039] Figure 12Treatment with exemplary 3,2-HPP metabolites significantly altered the cytokine environment in the TME. M3-9-M, after 14 days of orthotopic implantation into male JAX C57BL / 6 mice... OVA Cytokine levels in tumor stroma fluid isolated from tumor. Treatment with 3,2-HPP metabolites began 1 day after tumor implantation. (Two-stage combined experiment, one-way ANOVA test).

[0040] Figure 13 Exemplary HPP isoforms (I-1, I-2, and I-3) are shown to accelerate immune signaling pathways by promoting the cleavage of gasdermin D. ae, THP1-WT and THP1-GSDMD-KO cells were treated with LPS in the presence or absence of HPP metabolites. If necessary, IgG1 isotype (clone T8E5) or anti-IL-1α (clone 7D4) and anti-IL-1β (clone 4H5) antibodies were added to neutralize secreted IL-1 cytokines, and the supernatant was analyzed: a, THP1-Dual™ cells induced NF-κB (triple-combination experiment, one-way ANOVA test); b, HEK-Blue cells 4 hours later. TM IL-1β cell response to NF-κB / AP-1 induced by IL-1β signaling (triple-combination experiment, one-way ANOVA test); IL-1 secreted 16 hours after cd. α e, IL-1β level (two-combination experiment, one-way ANOVA test); f, LDH level released 16 hours later (three-combination experiment, one-way ANOVA test); fh, supernatant of NG THP1-WT and THP1-GSDMD-KO cells added after 3 hours of LPS treatment with or without HPP metabolites; f, HEK-Blue cells released 4 hours later. TM IL-1β cell response to NF-κB / AP-1 induced by IL-1β signaling (triple-combination experiment, one-way ANOVA); gh, LDH levels released at 4 and 16 hours (triple-combination experiment, one-way ANOVA); i, HEK-Blue TM The response of IFN-α / β cells (type I IFN signaling-induced IRF) to the supernatant of THP1-WT and THP1-GSDMD-KO cells treated with VSV in the presence or absence of HPP metabolites; the secretion of IL-1 was detected in the supernatant of human PBMCs treated with LPS for 3 hours in the presence or absence of HPP metabolites. α And IL-1β levels (two combined experiments, one-way ANOVA test).

[0041] Figure 14 This is a general schematic diagram illustrating how the exemplary microbiome-derived metabolite HPP contributes to antitumor immune responses.

[0042] Figure 15 The treatment of THP1-Dual with LPS in the presence of a solvent or exemplary compounds II-4, II-3, II-2, II-1, and I-3 is shown. TM Cells induced the NF-κB pathway after 16 hours.

[0043] Figure 16 The treatment of THP1-Dual with LPS in the presence of a solvent or exemplary compounds I-7, I-6, I-5, I-4, and I-3 is shown. TM Cells induced the NF-κB pathway after 16 hours.

[0044] Figure 17 The treatment of THP1-Dual with LPS in the presence of a solvent or exemplary compounds III-2, III-1, and I-3 is shown. TM Cells induced the NF-κB pathway after 16 hours.

[0045] Figure 18 The treatment of THP1-Dual with LPS in the presence of a solvent or exemplary compounds IV and I-3 is shown. TM Cells induced the NF-κB pathway after 16 hours. Detailed Implementation

[0046] I. Definition Unless otherwise stated, the definitions and implementations described in this and other sections are intended to apply to all implementations and aspects of this application described herein, and those skilled in the art should understand the applicability of these definitions and implementations.

[0047] All features disclosed in this specification (including the claims, abstract, and drawings), and all steps in any disclosed method or process, may be combined in any combination except for at least some mutually exclusive combinations of these features and / or steps. Unless otherwise expressly stated, each feature disclosed in this specification (including the claims, abstract, and drawings) may be replaced by an alternative feature for the same, equivalent, or similar purpose.

[0048] As used herein, the terms "compound of the application" or "compound of this application" refer to one or more compounds of formula (I), (II), (III) or (IV), including pharmaceutically acceptable salts, solvates and / or ester prodrugs thereof.

[0049] As used herein, the term "composition of the application" or "composition of this application" refers to a composition comprising one or more compounds of this application and at least one additional ingredient.

[0050] As used herein, the term "and / or" means that the listed items are present or used individually or in combination. In practice, this term means the use or presence of "at least one" or "one or more" of the listed items. With respect to pharmaceutically acceptable salts and / or solvates thereof, the term "and / or" means that the compounds of this application are present as a single salt and hydrate, and as a combination of solvates of, for example, salts of the compounds of this application.

[0051] Unless the context clearly indicates otherwise, the singular forms "a," "an," and "the" as used herein include plural references as well. For example, embodiments including "compound" should be understood to present certain aspects as one compound, or two or more additional compounds.

[0052] In embodiments that include an "additional" or "second" component (such as an additional compound or a second compound), the second component as used herein is chemically different from the other components or the first component. The "third" component is also different from the other, first and second components, as well as the further listed or "additional" components.

[0053] As used herein, the terms “comprising” (and any form of inclusion, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of inclusion, such as “include” and “includes”), or “containing” (and any form of containing, such as “contain” and “contains”) are inclusive or open-ended and do not exclude additional, unmentioned elements or process / method steps.

[0054] As used herein, the phrase "consisting of" and its derivatives are intended as closed terms that indicate the presence of the stated features, elements, components, groups, integers and / or steps, while excluding the presence of other unstated features, elements, components, groups, integers and / or steps.

[0055] The term "consistent with substantially" as used herein is intended to indicate the presence of the stated features, elements, components, groups, integers and / or steps, as well as those that do not materially affect the basic and novel features of these features, elements, components, groups, integers and / or steps.

[0056] The degree terms used in this article, such as "basically," "about," and "approximately," refer to a reasonable amount of deviation of the modified term such that the final result will not be significantly altered. If such deviation does not negate the meaning of the word it modifies, these degree terms should be interpreted as including at least ±5% of the deviation of the modified term.

[0057] As used herein, the term "suitable" means that the selection of a particular compound or conditions depends on the specific synthetic operation to be performed, the characteristics of the molecule to be transformed, and / or the specific use of the compound, but such selection is entirely within the skill of those skilled in the art. All process / method steps described herein should be carried out under conditions sufficient to provide the product shown. Those skilled in the art will understand that all reaction conditions, including, for example, reaction solvent, reaction time, reaction temperature, reaction pressure, reactant ratios, and whether the reaction should be carried out under an anhydrous or inert atmosphere, can be varied to optimize the yield of the desired product, and doing so is also within the skill of those skilled in the art.

[0058] This application involves many chemical terms and abbreviations used by those skilled in the art. However, for clarity and consistency, definitions of selected terms are provided.

[0059] As used in this article, the term "cell" refers to a single cell or multiple cells, including cells in cell cultures or cells in the body of a subject.

[0060] As used herein, the term "subject" includes all members of the animal kingdom, including mammals. Therefore, the methods and uses of this application are applicable to human therapeutics and veterinary applications.

[0061] The term "pharmaceutically acceptable" means that it is compatible with the treatment of the subject.

[0062] The term "pharmaceuticalally acceptable carrier" means a non-toxic solvent, dispersant, excipient, adjuvant, or other material that, when mixed with an active ingredient (such as one or more compounds of this application), forms a pharmaceutical composition, i.e., a dosage form that can be administered to a subject.

[0063] The term "pharmaceutically acceptable salt" means an acid addition salt or base addition salt that is suitable for or compatible with the treatment of the subject.

[0064] Acid addition salts suitable for or compatible with the treatment of the subject are any non-toxic organic or inorganic acid addition salts of any basic compound.

[0065] Suitable or therapeutically compatible base addition salts for subjects are any non-toxic organic or inorganic base addition salts of any acidic compound.

[0066] As used in this article, the term "prodrug" means a compound or a salt and / or solvation of a compound that is converted into an active drug upon administration.

[0067] As used in this article, the term "solvent" means a compound, or a salt or active ingredient of a compound, wherein molecules of a suitable solvent are incorporated into the crystal lattice.

[0068] The term "N" as used in this article, such as in "4N", refers to the unit symbol for equivalent concentration in "eq / L".

[0069] The term "M" as used in this article, such as in "4M", refers to the unit symbol for molar concentration in "moles / L".

[0070] The term "DMSO" used in this article refers to dimethyl sulfoxide.

[0071] The term "HCl" used in this article refers to hydrochloric acid.

[0072] The term "PBS" used in this article refers to phosphate-based buffer.

[0073] The term "RT" used in this article refers to room temperature.

[0074] The term "HPLC" used in this article refers to high-performance liquid chromatography.

[0075] The term "EDTA" used in this article refers to ethylenediaminetetraacetic acid.

[0076] The term "FBS" used in this article refers to fetal bovine serum.

[0077] The term "HPP" used in this article refers to hydroxyphenyl propionate.

[0078] The term "ICB" used in this article refers to immune checkpoint blockade.

[0079] The term "GSDMD" used in this article refers to gasdermin D.

[0080] The term "TME" used in this article refers to the tumor microenvironment.

[0081] The term "PCoA" used in this article refers to principal coordinate analysis.

[0082] The term "IMMD" as used in this article refers to genetically identical mice that are colonized with different complex microbiomes at birth.

[0083] The term "ABX" used in this article refers to antibiotics.

[0084] The term "UHPLC-MS" used in this article refers to ultra-high performance liquid chromatography-mass spectrometry.

[0085] The term "Tregs" used in this article refers to regulatory T cells.

[0086] The term "pDc" used in this article refers to plasmacytoid dendritic cells.

[0087] The term "TPP" used in this article refers to thermal proteomics sequencing analysis.

[0088] The term "ASV" used in this article refers to amplicon sequence variants.

[0089] The term "RBC" used in this article refers to red blood cells.

[0090] The term "PVDF" used in this article refers to polyvinylidene fluoride.

[0091] As used herein and as is well known in the art, the term "treatment" means a method used to achieve a beneficial or desired outcome, including clinical outcomes. Beneficial or desired clinical outcomes may include, but are not limited to, relief or improvement of one or more symptoms or conditions; reduction of the severity of a disease, disorder, or condition; stabilization (i.e., non-exacerbation) of the state of a disease, disorder, or condition; prevention of the spread of a disease, disorder, or condition; delay or slowing the progression of a disease, disorder, or condition; improvement or mitigation of the state of a disease, disorder, or condition; reduction of recurrence of a disease, disorder, or condition; and remission (whether partial or complete), whether detectable or undetectable. "Treatment" may also refer to an extension of life compared to expected life without treatment. As used herein, "treatment" also includes preventative treatment.

[0092] "Palliance" of a disease, disorder, or condition means that the severity and / or undesirable clinical manifestations of the disease, disorder, or condition are reduced, and / or the time course of its progression is slowed or prolonged, compared to an untreated disease, disorder, or condition.

[0093] As used in this article, the term "prevention" or its synonyms refer to reducing the risk or likelihood of a subject developing a disease, disorder, or condition, or exhibiting symptoms associated with a disease, disorder, or condition.

[0094] As used in this article, the term "effective amount" or "therapeutic effective amount" refers to the amount of one or more compounds that are effective at the dose and duration required to achieve the desired results.

[0095] The term "accelerated GSDMD cleavage" as used in this article refers to promoting the cleavage of the pore-forming protein gasdermin D (GSDMD) in cells. Increased cleavage can induce therapeutic effects in cells.

[0096] The terms “increase” or “enhance” or any of their synonyms, including “improvement”, “acceleration”, etc., mean any detectable increase in the function or quantity of the target substance in the presence of one or more compounds of this application, compared to other cases under the same conditions but without the presence of one or more compounds of this application.

[0097] The terms "reduction" or "reduction" or any of their synonyms, including "decline," "reduction," etc., mean any detectable reduction in the function or quantity of the target substance in the presence of one or more compounds of this application, compared to other cases under the same conditions but without the presence of one or more compounds of this application.

[0098] As used herein, the term "application" means administering a therapeutically effective amount of the compound of this application, or one or more compounds or compositions, to a cell or subject.

[0099] II. Methods and uses of this application The compounds in this application have been shown to enhance antitumor immunity and synergize with immune checkpoint blockade (ICB) therapy. HPP molecules act as a broad-spectrum enhancer of innate immune signaling pathways in tumor-associated myeloid cells by promoting the cleavage of the pore-forming protein gasdermin D (GSDMD, an effector of both typical and atypical inflammasome signaling). HPP-treated myeloid cells secrete increased levels of pro-inflammatory cytokines (including IL-1β), thereby promoting NF-κB activity within tumor-infiltrating leukocytes. This results in improved function of anti-cancer CD8 T cells in mice, significant tumor regression, and better long-term control of cancer with immune checkpoint therapy. Human peripheral blood mononuclear cells have also shown a similar response to HPP treatment. GSDMD cleavage has also been associated with a favorable response to ICB therapy in patients with advanced melanoma. In summary, this application identifies a previously unknown microbiome-mediated host antitumor immune modulation mechanism that can be altered and used to enhance the efficacy of cancer immunotherapy.

[0100] Therefore, this application includes a method for increasing anti-tumor immunity in biological samples or subject cells, comprising administering an effective amount of one or more compounds of this application to the cells in need.

[0101] In some embodiments, the compounds of this application are compounds of formula (I) or pharmaceutically acceptable salts, solvates, and / or ester prodrugs thereof:

[0102] in R 1 R 2 and R 3 It can be OH or H independently, provided that R is present.1 R 2 and R 3 At least one of them is OH.

[0103] In some embodiments, the compounds of this application are selected from the following:

[0104] Or a pharmaceutically acceptable salt, solvate, and / or ester prodrug.

[0105] In some embodiments, the compounds of the application are selected from the following:

[0107] In some embodiments, the compounds of this application are compounds of formula (II), (III), or (IV) or their pharmaceutically acceptable salts, solvates, and / or ester prodrugs:

[0108] in R 4 Selected from halogens, NR 5 R 6 and C 1-3 Alkyl groups; and R 5 and R 6 Independently selected from H and C 1-3 alkyl;

[0109] in R 7 It is OH; and n is 3-5; or (V).

[0110] In some embodiments, the compound of formula (II) or its pharmaceutically acceptable salt, solvate, and / or ester prodrug has the following structure:

[0111] Where R 4 As defined in Equation II.

[0112] In some implementations, R 4 Selected from F, Cl, NH2 and CH3.

[0113] In some embodiments, the compound of formula (III) or its pharmaceutically acceptable salt, solvate, and / or ester prodrug has the following structure:

[0114] Where R 7 And n is as defined in Equation III.

[0115] In some embodiments, the compound of formula (IV) or its pharmaceutically acceptable salt, solvate, and / or ester prodrug has the following structure: (IV).

[0116] In some embodiments, the compounds of this application are selected from the following:

[0117] Or a pharmaceutically acceptable salt, solvate, and / or ester prodrug.

[0118] In some embodiments, the compounds of this application are selected from compounds of formula (V) or their pharmaceutically acceptable salts, solvates, and / or ester prodrugs:

[0119] in R 8 R 9 and R 10 It is OH or H independently, provided that R is present. 8 R 9 and R 10 At least one of them is OH, or R 8 R 9 and R 10 One of them is selected from halogen, NR 13 R 14 and C 1-3 Alkyl groups, and R 8 R 9 and R 10 The other two are H; R 13 and R 14 Independently selected from H and C 1-3 alkyl; R 11 Selected from H and =O; R 12 Selected from H, C 1-4 Alkyl and succinimide; and p is 1-4.

[0120] In some implementations, R 8 R 9 and R 10 It is OH or H independently, provided that R is present. 8 R 9 and R10 At least one of them is OH. In some embodiments, R 10 It is OH, R 8 and R 9 It is H. In some implementations, R 9 It is OH, R 8 and R 10 It is H. In some implementations, R 8 It is OH, R 9 and R 10 It is H.

[0121] In some implementations, R 8 Selected from halogens, NR 13 R 14 and C 1-3 Alkyl; and R 9 and R 10 It is H. In some implementations, R 8 Selected from F, Cl, NH2 and CH3, and R 9 and R 10 It is H.

[0122] In some implementations, R 11 It is H. In some implementations, R 11 Yes = O.

[0123] In some implementations, R 12 Selected from H, C 1-3 Alkyl groups and succinimides. In some embodiments, R 12 It is H. In some implementations, R 12 It is CH2-CH3 or CH3. In some embodiments, R 12 It is succinimide.

[0124] In some implementations, p is 1. In some implementations, p is 2 or 3.

[0125] In some implementations, R 8 It is OH, R 9 and R 10 It is H, R 11 It is H, R 12 H is H, and p is 1.

[0126] In some implementations, R 9 It is OH, R 8 and R 10 It is H, R 11 It is H, R 12 H is H, and p is 1.

[0127] In some implementations, R10 It is OH, R 8 and R 9 It is H, R 11 It is H, R 12 H is H, and p is 1.

[0128] In some implementations, R 8 It is OH, R 9 and R 10 It is H, R 11 It is H, R 12 Selected from H, CH2-CH3, CH3 and succinimide, and p is 1.

[0129] In some implementations, R 8 Selected from F, Cl, NH2 and CH3, R 9 and R 10 It is H, R 11 It is H, R 12 H is H, and p is 1.

[0130] In some implementations, R 8 It is OH, R 9 and R 10 It is H, R 11 It is H, R 12 It is H, and p is 2 or 3.

[0131] In some implementations, R 8 It is OH, R 9 and R 10 It is H, R 11 It is C(O), and p is 2.

[0132] In some embodiments, the pharmaceutically acceptable salt is a base addition salt. Those skilled in the art can select a suitable salt (see, for example, SM Berge, et al., "Pharmaceutical Salts," J.Pharm.Sci.1977, 66, 1-19).

[0133] In some embodiments, the base addition salt suitable for or compatible with the treatment of the subject is any non-toxic organic or inorganic base addition salt of a compound of formula (1). Exemplary inorganic bases that form suitable salts include lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, or barium hydroxide, as well as ammonia. Exemplary organic bases that form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as isopropylamine, methylamine, trimethylamine, methylpyridine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. In some implementations, the pharmaceutically acceptable salt is a sodium salt.

[0134] Solvents of compounds of formula (I) or their salts or ester prodrugs include, for example, solvates prepared with pharmaceutically acceptable solvents. Examples of such solvents include water (the resulting solvate is called a hydrate) and ethanol. A suitable solvent is physiologically tolerable at the administered dose.

[0135] The prodrugs of the compounds in this application can be, for example, conventional esters formed with available hydroxyl and / or carboxyl groups. Some commonly used esters as prodrugs are phenyl esters, aliphatic (C1-C4) esters, and others. 24 Esters, acyloxymethyl esters, carbamates, and amino acid esters. In some embodiments, the prodrug is a methyl ester, an ethyl ester, or an N-hydroxysuccinimide ester.

[0136] The compounds of this application may also exist in different polymorphic forms, and it is envisioned that any polymorph or mixture thereof is included within the scope of this application.

[0137] This application also includes the use of one or more compounds of this application for enhancing cellular antitumor immunity, and the use of one or more compounds of this application for preparing a medicament for enhancing cellular antitumor immunity. This application also includes one or more compounds of this application for enhancing cellular antitumor immunity.

[0138] Since the compounds of this application have been shown to increase anti-tumor immunity, they can be used to treat diseases, disorders or conditions by increasing anti-tumor immunity in biological samples or subject cells.

[0139] Therefore, this application also includes a method for treating a disease, disorder, or condition that can be treated by increasing antitumor immunity in biological samples or subject cells, said method comprising administering a therapeutically effective amount of one or more compounds of this application to the cells.

[0140] This application also includes the use of one or more compounds of this application for treating diseases, disorders, or conditions that can be treated by increasing anti-tumor immunity in cells, and the use of one or more compounds of this application for preparing a medicament for treating diseases, disorders, or conditions that can be treated by increasing anti-tumor immunity in cells. This application also includes one or more compounds of this application for treating diseases, disorders, or conditions that can be treated by increasing anti-tumor immunity in cells.

[0141] In some embodiments, this application also includes the use of one or more compounds of this application for treating diseases, disorders, or conditions that can be treated by increasing GSDMD lysis in cells, and the use of one or more compounds of this application for preparing a medicament for treating diseases, disorders, or conditions that can be treated by increasing GSDMD lysis in cells. This application also includes one or more compounds of this application for treating diseases, disorders, or conditions that can be treated by increasing GSDMD lysis in cells.

[0142] In some embodiments, this application also includes the use of one or more compounds of this application for treating diseases, disorders, or conditions that can be treated by increasing the release of tumor-stromal IL-1β and the accumulation of tumor-specific CD8 T cells in the TME, and the use of one or more compounds of this application for preparing a medicament for treating diseases, disorders, or conditions that can be treated by increasing the release of tumor-stromal IL-1β and the accumulation of tumor-specific CD8 T cells in the TME. This application also includes one or more compounds of this application for treating diseases, disorders, or conditions that can be treated by increasing the release of tumor-stromal IL-1β and the accumulation of tumor-specific CD8 T cells in the TME.

[0143] The compounds of this application have been shown to increase anti-tumor immunity in cancer cells. In some embodiments, the disease, disorder, or ailment that can be treated by increasing anti-tumor immunity is cancer.

[0144] Therefore, this application also includes a method of treating cancer, the method comprising administering a therapeutically effective amount of one or more compounds of this application to a subject in need. This application also includes the use of one or more compounds of this application for treating cancer, and the use of one or more compounds of this application for preparing a medicament for treating cancer. This application also includes one or more compounds of this application for treating cancer.

[0145] In some embodiments, the cancer is selected from, but not limited to: acute lymphoblastic leukemia (ALL), adults; acute lymphoblastic leukemia (ALL), children; acute myeloid leukemia (AML), adults; adrenocortical carcinoma; adrenocortical carcinoma, children; HIV-associated lymphoma; HIV-associated malignancies; anal cancer; astrocytoma, cerebellum in children; astrocytoma, brain in children; bile duct cancer, extrahepatic; bladder cancer; bladder cancer, children; bone cancer, osteosarcoma / malignant fibrous histiocytoma; brainstem glioma, children; brain tumor, adults; brain tumor, brainstem glioma, children; brain tumor, cerebellar astrocytoma, children; brain tumor, cerebral astrocytoma / malignant glioma, children; brain tumor, ependymoma, children; brain tumor, medulloblastoma, children; brain tumor, tentorial tubercle Upper primitive neuroectodermal tumors, children; brain tumors, visual pathway and hypothalamic gliomas, children; brain tumors, children (other); breast cancer; breast cancer and pregnancy; breast cancer, children; breast cancer, men; bronchial adenoma / carcinoid, children; carcinoid tumors, children; carcinoid tumors, gastrointestinal tract; carcinoma, adrenal cortex; carcinoma, islet cells; primary cancer of unknown origin; central nervous system lymphoma, primary; cerebellar astrocytoma, children; cerebral astrocytoma / malignant glioma, children; cervical cancer; childhood cancer; chronic lymphocytic leukemia; chronic myeloid leukemia; chronic myelodysplastic syndrome; clear cell sarcoma of the tendon sheath; colon cancer; colorectal cancer, children; cutaneous T-cell lymphoma; endometrial cancer; ependymoma, children; epithelial carcinoma. Ovarian; Esophageal cancer; Esophageal cancer, children; Ewing familial cancer; Extracranial germ cell tumors, children; Extragonadal germ cell tumors; Extrahepatic bile duct cancer; Ocular cancer, intraocular melanoma; Ocular cancer, retinoblastoma; Gallbladder cancer; Gastric cancer; Gastric cancer, children; Gastrointestinal carcinoid tumors; Germ cell tumors, extracranial, children; Germ cell tumors, extragonadal; Germ cell tumors, ovaries; Gestational trophoblastic tumors; Glioma, pediatric brainstem; Glioma, pediatric visual pathway and hypothalamus; Hairy cell leukemia; Head and neck cancer; Hepatocellular carcinoma, adults (primary); Hepatocellular carcinoma, children (primary); Hodgkin lymphoma, adults; Hodgkin lymphoma, children; Hodgkin lymphoma during pregnancy; Hypopharyngeal cancer; Hypothalamic and visual pathway gliomas, children Intraocular melanoma; Islet cell carcinoma (endocrine pancreas); Kaposi's sarcoma; Renal cell carcinoma; Laryngeal cancer; Laryngeal cancer, children; Leukemia, acute lymphoblastic, adults; Leukemia, acute lymphoblastic, children; Leukemia, acute myeloid, adults; Leukemia, acute myeloid, children; Leukemia, chronic lymphoblastic; Leukemia, chronic myeloid; Leukemia, hair cell; Lip and oral cancer; Liver cancer, adults (primary); Liver cancer, children (primary); Lung cancer, non-small cell; Lung cancer, small cell; Lymphocytic leukemia, acute in adults; Lymphocytic leukemia, acute in children; Lymphocytic leukemia, chronic; Lymphoma, AIDS-related; Lymphoma, central nervous system (primary); Lymphoma, cutaneous T-cell; Lymphoma, Hodgkin's, adults;Lymphoma, Hodgkin's, Children; Lymphoma, Hodgkin's during Pregnancy; Lymphoma, Non-Hodgkin's, Adults; Lymphoma, Non-Hodgkin's, Children; Lymphoma, Non-Hodgkin's during Pregnancy; Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenström; Male Breast Cancer; Malignant Mesothelioma, Adults; Malignant Mesothelioma, Children; Malignant Thymoma; Medulloblastoma, Children; Melanoma; Melanoma, Intraocular; Merkel Cell Carcinoma; Mesothelioma, Malignant; Metastatic Squamous Cell Carcinoma of the Neck with Unknown Primary Location; Multiple Endocrine Neoplasia Syndrome, Children; Multiple Myeloma / Plasma Cell Tumor; Mycosis Fungoides; Myelodysplastic Syndrome; Myeloid Leukemia, Chronic; Myeloid Leukemia, Children Acute myeloma in children; multiple myeloma; myelodysplastic dysplasia, chronic; nasal and paranasal sinus carcinoma; nasopharyngeal carcinoma; nasopharyngeal carcinoma, children; neuroblastoma; non-Hodgkin lymphoma, adults; non-Hodgkin lymphoma, children; non-Hodgkin lymphoma during pregnancy; non-small cell lung cancer; oral cancer, children; oral and lip cancer; oropharyngeal cancer; osteosarcoma / malignant fibrous histiocytoma; ovarian cancer, children; ovarian epithelial carcinoma; ovarian germ cell tumors; low-potency ovarian tumors; pancreatic cancer; pancreatic cancer, children; pancreatic cancer, islet cells; sinus and nasal cavity carcinoma; parathyroid carcinoma; penile cancer; pheochromocytoma; pineal and supratentorial primitive neuroectodermal tumors, children; pituitary tumors; plasma cell tumors / multiple myeloma Tumors; Pleural pulmonary blastoma; Pregnancy complicated with breast cancer; Pregnancy complicated with Hodgkin lymphoma; Pregnancy complicated with non-Hodgkin lymphoma; Primary central nervous system lymphoma; Primary liver cancer, adults; Primary liver cancer, children; Prostate cancer; Rectal cancer; Renal cell (kidney) carcinoma; Renal cell carcinoma, children; Transitional cell carcinoma of the renal pelvis and ureter; Retinoblastoma; Rhabdomyosarcoma, children; Salivary gland cancer; Salivary gland cancer, children; Sarcoma, Ewing family tumor; Sarcoma, Kaposi's; Sarcoma (osteosarcoma) / malignant fibrous histiocytoma of bone; Sarcoma, rhabdomyosarcoma, children; Sarcoma, soft tissue, adults; Sarcoma, soft tissue, children; Cezari syndrome; Skin cancer; Skin cancer, children; Skin cancer (Melanoma); Skin cancer, Merkel cell; Small cell lung cancer; Small bowel cancer; Soft tissue sarcoma, adults; Soft tissue sarcoma, children; Neck squamous cell carcinoma of unknown primary origin, metastatic; Gastric cancer; Gastric cancer, children; Supratentorial primitive neuroectodermal tumor, children; T-cell lymphoma, skin; Testicular cancer; Thymoma, children; Thymoma, malignant; Thyroid cancer; Thyroid cancer, children; Transitional cell carcinoma of the renal pelvis and ureter; Trophoblastic tumor, pregnancy; Cancer of unknown primary origin, children; Rare childhood cancers; Transitional cell carcinoma of the ureter and renal pelvis; Urethral cancer; Uterine sarcoma; Vaginal cancer; Visual pathway and hypothalamic glioma, children; Vulvar cancer; Waldenström macroglobulinemia; and Nephroblastoma. Metastases of the above cancers can also be treated according to the methods described in this article.

[0146] In some embodiments, the cancer is selected from one or more of solid tumors, breast cancer, colon cancer, bladder cancer, skin cancer, head and neck cancer, liver cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, bone cancer, and glioblastoma. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is skin cancer. In some embodiments, the cancer is head and neck cancer. In some embodiments, the cancer is colorectal cancer (CRC). In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is osteosarcoma.

[0147] This application also includes a method for treating a disease, disorder, or condition that can be treated by increasing anti-tumor immunity in biological samples or subject cells, comprising administering a therapeutically effective amount of one or more compounds of this application to cells, in combination with another agent for treating a disease, disorder, or condition that can be treated by enhancing anti-tumor immunity. This application also includes the use of one or more compounds of this application in combination with another agent for treating a disease, disorder, or condition that can be treated by enhancing anti-tumor immunity, and the use of one or more compounds of this application in combination with another agent for treating a disease, disorder, or condition that can be treated by enhancing anti-tumor immunity to prepare a medicament for treating a disease, disorder, or condition that can be treated by enhancing anti-tumor immunity. This application also includes one or more compounds of this application in combination with another agent for treating a disease, disorder, or condition that can be treated by enhancing anti-tumor immunity, for treating a disease, disorder, or condition that can be treated by enhancing anti-tumor immunity.

[0148] In some embodiments, GSDMD is cleaved in the uses and methods of this application.

[0149] In one implementation, the subject is a subject suffering from a disease, disorder, or condition.

[0150] In one implementation, the subject is a mammal. In another implementation, the subject is a human.

[0151] In some embodiments, the disease, disorder, or condition that can be treated by increasing anti-tumor immunity is cancer, and one or more of the compounds of this application are administered or used in combination with one or more additional agents and / or cancer therapies for treating cancer.

[0152] This application also includes a method for enhancing the efficacy of one or more adjunct agents and / or cancer therapies for treating cancer, comprising administering an effective amount of one or more compounds of this application to a subject in need, in combination with an effective amount of one or more adjunct agents and / or cancer therapies for treating cancer.

[0153] This application also includes the use of one or more compounds of this application in combination with one or more adjuncts and / or cancer therapies for enhancing the efficacy of one or more adjuncts and / or cancer therapies in treating cancer. This application also includes the use of one or more compounds of this application in combination with one or more adjuncts and / or cancer therapies for enhancing the efficacy of one or more adjuncts and / or cancer therapies in treating cancer.

[0154] In some embodiments, one or more adjunctive agents for treating cancer are, for example, small molecule chemotherapy agents such as cisplatin, tyrosine kinase inhibitors, glutaminase inhibitors (such as glutaminase-1 (GLS1) inhibitors), and asparagine synthase (ASNS) inhibitors. In some embodiments, the cancer therapy is, for example, radiation therapy, targeted therapy such as antibody therapy (including anti-PD-1 and / or anti-PD-L1 antibodies), immunotherapy, hormone therapy, and anti-angiogenic therapy.

[0155] In some embodiments, the immunotherapy is an immune checkpoint blockade therapy. In some embodiments, the immune checkpoint blockade therapy is a PD-1 inhibitor, including one or more of pembrolizumab, nivolumab, and cimiplimab; or a PD-L1 inhibitor, including one or more of atezolizumab, avelumab, and durvalumab. In some embodiments, the immune checkpoint blockade therapy is a CTLA-4 inhibitor, including ipilimumab and / or tremelimumab. In some embodiments, the immune checkpoint blockade therapy is a LAG-3 inhibitor, including relatlimab and / or opdualag.

[0156] In some embodiments, chemotherapy is a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is cisplatin. Therefore, in some embodiments, the disease, disorder, or condition that can be treated by increasing antitumor immunity is cancer, and one or more compounds of this application are administered or used in combination with cisplatin. In some embodiments, the chemotherapeutic agent is L-asparaginase (L-ASNase). Therefore, in some embodiments, the disease, disorder, or condition that can be treated by increasing antitumor immunity is cancer, and one or more compounds of this application are administered or used in combination with L-asparaginase (L-ASNase).

[0157] In some embodiments, the small molecule therapy is a glutaminase (such as a glutaminase-1 (GLS1)) inhibitor or an asparagine synthase (ASNS) inhibitor. Therefore, in some embodiments, the disease, disorder, or condition that can be treated by increasing anti-tumor immunity is cancer, and one or more compounds of this application are administered or used in combination with one or more glutaminase inhibitors (such as GLS1 inhibitors) and / or asparagine synthase (ASNS) inhibitors.

[0158] In some embodiments, the disease, disorder, or condition that can be treated by increasing anti-tumor immunity is cancer, and one or more compounds of this application are administered or used in combination with one or more glutaminase inhibitors (such as GLS1 inhibitors) and / or asparagine synthase (ASNS) inhibitors and / or L-asparaginease (L-ASNase).

[0159] When used in combination with other agents for treating diseases, disorders, conditions, or cancers that can be treated by increasing antitumor immunity, one embodiment is that the compound of this application is administered simultaneously with these agents. As used herein, "simultaneous administration" of two substances to a subject means providing each of the two substances so that they are simultaneously biologically active in the individual. The exact details of administration will depend on the pharmacokinetics of the two substances in the presence of each other and may include administering the two substances several hours apart, or, if pharmacokineticly appropriate, even administering the other substance within 24 hours after administering one substance. It is conventional for those skilled in the art to devise suitable administration regimens. In certain embodiments, the two substances will be administered substantially simultaneously, i.e., several minutes apart, or in a single composition containing both substances. Another embodiment of this application is a combination of agents administered to a subject in a non-simultaneous manner. In some embodiments, the compound of this application is administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms, or together in a single unit dosage form. Thus, this application provides a single unit dosage form comprising one or more compounds of this application, an additional therapeutic agent, and a pharmaceutically acceptable carrier.

[0160] Treatment methods include administering a therapeutically effective amount of one or more compounds of this application to a subject, optionally consisting of a single administration, or optionally including a series of administrations, and optionally including simultaneous administration or use of one or more other therapeutic agents. For example, in some embodiments, the compounds of this application may be administered at least once a week. In some embodiments, for a given treatment, the compound may be administered to the subject about once every two or three weeks, or about once a week to about once a day. In another embodiment, the compound is administered 2, 3, 4, 5, or 6 times daily. The length of the treatment period depends on a variety of factors, such as the severity of the disease, disorder, or condition, the age of the subject, the concentration and / or activity of the compound of this application, and / or combinations thereof. It should also be recognized that the effective dose of the compound used for treatment may be increased or decreased during a particular treatment regimen. Changes in dose can be produced by standard diagnostic assays known in the art and become apparent. In some cases, prolonged administration may be required. For example, the compound may be administered to the subject in an amount and for a duration sufficient to treat the subject. In some embodiments, the treatment includes prophylactic treatment. For example, it can be used to treat patients with early-stage cancer to prevent progression, or optionally to treat subjects in remission with the compounds or compositions of this application to prevent recurrence.

[0161] The dosage of the compounds in this application may vary depending on many factors, such as the pharmacodynamic properties of the compound, the route of administration, the recipient's age, health and weight, the nature and severity of symptoms, the frequency of treatment and the type of concurrent treatment (if any), and the clearance rate of the compound in the treated subject. Those skilled in the art can determine an appropriate dosage based on the above factors. The compounds in this application may initially be administered at a suitable dosage, which may be adjusted as needed based on clinical response. The dosage is typically chosen to maintain serum levels of the compounds in this application at about 0.01 µg / cc to about 1000 µg / cc, or about 0.1 µg / cc to about 100 µg / cc. As a representative example, the oral dosage of one or more compounds of this application for use in adults ranges from about 0.05 mg / day to about 1000 mg / day, suitably from about 0.1 mg / day to about 500 mg / day, and more suitably from about 1 mg / day to about 200 mg / day. For parenteral administration, representative dosages are about 0.001 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 1 mg / kg, or about 0.1 mg / kg to about 1 mg / kg. For oral administration, representative dosages are about 0.001 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 1 mg / kg, or about 0.1 mg / kg to about 1 mg / kg. For suppository administration, representative dosages are about 0.1 mg / kg to about 10 mg / kg, or about 0.1 mg / kg to about 1 mg / kg. The compounds in this application can be administered as a single daily dose, a weekly dose, or a monthly dose, or the total daily dose can be divided into two, three, or four daily doses.

[0162] In one embodiment, the effective amount varies based on factors such as the subject's disease state, age, sex, and / or weight. In another embodiment, the amount of one or more given compounds corresponding to the effective amount will vary based on a variety of factors, such as the given drug or compound, the drug formulation, the route of administration, the type of condition, disease, or disorder, and the identity of the subject receiving treatment, but can still be determined conventionally by those skilled in the art. 。

[0163] It should be noted that, in the above text, the term "compound" also includes embodiments in which one or more compounds are mentioned. Similarly, the term "compound of this application" also includes embodiments in which only one compound is mentioned.

[0164] The compounds of this application can be suitably formulated into pharmaceutical compositions for administration to subjects in a biocompatible form suitable for in vivo administration. Therefore, this application also includes a pharmaceutical composition comprising one or more compounds of this application and a pharmaceutically acceptable carrier. In embodiments of this application, the pharmaceutical composition is used to treat any disease, disorder, or condition described herein, and one or more compounds of this application are present in the composition in an amount that can effectively increase antitumor immunity or treat cancer.

[0165] Those skilled in the art will understand that, depending on the chosen route of administration, the compounds of this application can be administered to a subject in a variety of forms. For example, the compounds of this application can be administered orally, by inhalation, parenteral administration, oral, sublingual, nasal, rectal, vaginal administration, by patch, pump, micropump, topical or transdermal administration, and accordingly formulated pharmaceutical compositions. In some embodiments, administration may be carried out periodically or continuously via a pump. Conventional procedures and ingredients for selecting and preparing suitable compositions are described, for example, in the following literature: Remington's Pharmaceutical Sciences (2000–20th edition) and The United States Pharmacopeia: The National Formulary (USP 24NF19), published in 1999.

[0166] Parenteral administration includes systemic delivery routes other than the gastrointestinal (GI) tract, and includes, for example, intravenous, intra-arterial, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary (e.g., by using an aerosol), intrathecal, rectal, and local (including by using a patch or other percutaneous delivery device) administration modes. Parenteral administration can be a continuous infusion over a selected time period.

[0167] In some embodiments, the compounds of this application can be administered orally, for example, with an inert diluent or an absorbable edible carrier, or encapsulated in hard or soft-shell gelatin capsules, or compressed into tablets, or directly incorporated into dietary foods. In some embodiments, the compounds can be incorporated with excipients and used in the form of ingestible tablets, lozenges, trochetes, capsules, capsule tablets, pills, granules, lozenges, chewing gum, powders, syrups, elixirs, wafers, aqueous solutions, and suspensions. In the case of tablets, the carriers used include lactose, corn starch, sodium citrate, and phosphates. Pharmaceutically acceptable excipients include binders (e.g., pregelatinized corn starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose, or calcium phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disintegrants (e.g., potato starch or sodium carboxymethyl starch); or wetting agents (e.g., sodium dodecyl sulfate). In this embodiment, the tablets may be coated using methods well known in the art. In the case of tablets, capsules, pouches, pills, or granules intended for oral administration, a pH-sensitive enteric coating designed to control the release of the active ingredient, such as Eudragits, may optionally be used. TM Oral dosage forms also include modified release formulations (e.g., immediate release and timed release). Examples of modified release formulations include, for example, sustained-release (SR), extended-release (ER, XR, or XL), sustained-release or timed-release, controlled-release (CR), or continuous-release (CR or Contin) forms, such as coated tablets, permeable delivery devices, coated capsules, microencapsulated microspheres, aggregated particles (e.g., molecular sieve-type particles), or bundles of fine hollow permeable fibers or shredded hollow permeable fibers aggregated or retained in a fiber package. Timed-release compositions, such as liposomes or those in which the active compound is protected by different degradable coatings, can be formulated, for example, by microencapsulation, multiple coatings, etc. Liposome delivery systems include, for example, small monolayer capsules, large monolayer capsules, and multilayer capsules. In some embodiments, liposomes may be formed from various phospholipids, such as cholesterol, stearamine, or phosphatidylcholine. For oral administration in capsule form, available carriers or diluents include lactose and dried corn starch.

[0168] In some embodiments, liquid formulations for oral administration may be in the form of, for example, solutions, syrups, or suspensions, or they may be suitably presented as dry products for reconstitution with water or other suitable solvents prior to use. When administering aqueous suspensions and / or emulsions orally, the compounds of this application are suitably suspended or dissolved in an oil phase in combination with emulsifiers and / or suspending agents. If desired, certain sweeteners and / or flavoring agents and / or coloring agents may be added. Such liquid formulations for oral administration may be prepared by conventional methods with pharmaceutically acceptable additives, such as suspending agents (e.g., pear syrup, methylcellulose, or hydrogenated edible fats); emulsifiers (e.g., lecithin or gum arabic); non-aqueous solvents (e.g., almond oil, oily esters, or ethanol); and preservatives (e.g., methylparaben or propylparaben or sorbic acid). Available diluents include lactose and high molecular weight polyethylene glycol.

[0169] The compounds of this application can also be freeze-dried, and the resulting freeze-dried products can be used, for example, to prepare injectable products.

[0170] In some embodiments, the compounds of this application can be administered parenterally. For example, solutions of the compounds of this application can be prepared in water appropriately mixed with a surfactant (e.g., hydroxypropyl cellulose). In some embodiments, dispersions can be prepared in glycerol, liquid polyethylene glycol, DMSO, and mixtures thereof with or without alcohol, or in oil. Under normal storage and use conditions, these formulations contain preservatives to prevent microbial growth. Those skilled in the art understand how to prepare suitable formulations. For parenterally administration, a sterile solution of the compounds of this application is typically prepared, and the pH of the solution is appropriately adjusted and buffered. For intravenous use, the total concentration of the solute should be controlled to make the formulation isotonic. For ocular application, ointments or eye drops can be delivered, for example, via ocular delivery systems known in the art (e.g., applicators or eye drops). In some embodiments, such compositions may contain mucosal mimics, such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose, or polyvinyl alcohol; preservatives, such as sorbic acid, EDTA, or benzyl chromium chloride; and a typical amount of diluent or carrier. For lung application, choose a diluent or carrier suitable for forming an aerosol.

[0171] In some embodiments, the compounds of this application may be formulated for parenteral administration by injection, including using conventional catheter insertion or infusion. The injectable formulation may be present, for example, in unit dosage forms contained in preservative-added ampoules or multi-dose containers. In some embodiments, the composition may be in the form of a sterile suspension, solution, or emulsion in an oily or aqueous solvent, and may contain formulations such as suspending agents, stabilizers, and / or dispersants. In all cases, the form must be sterile and must be fluid for ease of injection. Optionally, the compounds of this application are suitably in sterile powder form for reconstitution with a suitable solvent (e.g., sterile pyrogen-free water) prior to use.

[0172] In some embodiments, compositions for nasal administration can be conveniently formulated as aerosols, drops, gels, and powders. For intranasal or inhalation administration, the compounds of this application are conveniently delivered in the form of solutions, dry powders, or granules or suspensions from a pump-operated spray container squeezed or pumped by a patient, or in the form of aerosol sprays from a pressurized container or nebulizer. Aerosol formulations typically comprise solutions or fine suspensions of the active substance in physiologically acceptable aqueous or non-aqueous solvents and are typically present in a sterile, single- or multiple-dose form in a sealed container, which may, for example, take the form of a cartridge or filler used with a nebulizer. Optionally, the sealed container is a single dispensing device, such as a single-dose nasal inhaler or an aerosol dispenser equipped with a metering valve designed for post-use disposal. In the case where the dosage form includes an aerosol dispenser, it may contain a propellant, which may be, for example, a compressed gas (e.g., compressed air) or an organic propellant (e.g., chlorofluorocarbons). Suitable propellants include, but are not limited to, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, heptafluoroalkane, carbon dioxide, or other suitable gases. In the case of pressurized aerosols, the dosage unit is appropriately determined by providing a valve to deliver the metering. In some embodiments, the pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (e.g., made of gelatin) for use in inhalers or blow-throughs may be formulated as powder mixtures containing the compounds of this application, and a suitable powder matrix (e.g., lactose or starch). Aerosol dosage forms may also be in the form of pump-type nebulizers.

[0173] Compositions suitable for oral or sublingual administration include tablets, lozenges, and lozenges, wherein the active ingredient is formulated together with a carrier (e.g., sugar, gum arabic, astragalus gum, or gelatin and glycerin). Compositions for rectal administration are conveniently in suppository form containing a conventional suppository base (e.g., cocoa butter).

[0174] The suppository form of the compounds described in this application is for vaginal, urethral, ​​and rectal administration. Such suppositories typically consist of a mixture of substances that are solid at room temperature but melt at body temperature. Substances commonly used to manufacture such solvents include, but are not limited to, cocoa butter (also known as cocoa brittle), glycerin gelatin, other glycerides, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights, and fatty acid esters of polyethylene glycol. See, for example, Remington's Pharmaceutical Sciences, 16th Ed., Mack Publishing, Easton, PA, 1980, pp. 1530-1533, for further discussion on suppository dosage forms.

[0175] In some embodiments, the compounds of this application may also be coupled with soluble polymers as targeted drug carriers. Such polymers include, for example, polyvinylpyrrolidone, pyran copolymers, polyhydroxypropyl methacrylamide-phenol, polyhydroxyethyl asparagine-phenol, or polyethylene oxide-polylysine substituted with palmitoyl residues. Furthermore, in some embodiments, the compounds of this application may be coupled with a class of biodegradable polymers that can be used to achieve controlled drug release, such as polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, polyepsilon caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyran, polycyanoacrylates, and crosslinked or amphiphilic block copolymers of hydrogels.

[0176] In some embodiments, the compounds of this application may be conjugated to viruses, non-viruses, or other vectors. Viral vectors may include retroviruses, lentiviruses, adenoviruses, herpesviruses, poxviruses, alphaviruses, vaccinia viruses, or adeno-associated viruses. Non-viral vectors may include nanoparticles, cationic lipids, cationic polymers, metal nanoparticles, nanorods, liposomes, micelles, microbubbles, cell-penetrating peptides, or lipoglobules. Nanoparticles may include silica, lipids, carbohydrates, or other pharmaceutically acceptable polymers.

[0177] The compounds of this application are suitable for use alone, but are generally administered in the form of pharmaceutical compositions, wherein one or more compounds of this application (active ingredients) are combined with a pharmaceutically acceptable carrier. Depending on the administration method, the pharmaceutical composition will comprise about 0.05 wt% to about 99 wt% or about 0.10 wt% to about 70 wt% of the active ingredient, and about 1 wt% to about 99.95 wt% or about 30 wt% to about 99.90 wt% of a pharmaceutically acceptable carrier, all weight percentages being based on the total weight of the composition.

[0178] In some embodiments, the pharmaceutical composition of this application further comprises one or more additional agents for treating cancer.

[0179] In some embodiments, one or more adjunctive agents for treating cancer are, for example, cisplatin, tyrosine kinase inhibitors, glutaminase inhibitors (e.g., glutaminase-1 (GLS1) inhibitors), asparagine synthase (ASNS) inhibitors, immune checkpoint blockers, or antibody therapies (including anti-PD-1 and / or anti-PD-L1 antibodies).

[0180] In some embodiments, one or more adjunctive agents for treating cancer are, for example, immune checkpoint inhibitors. In some embodiments, the immune checkpoint inhibitor is a PD-1 inhibitor, including one or more of pembrolizumab, nivolumab, and cimipril, or a PD-L1 inhibitor, including one or more of atezolizumab, avelumab, and durvalumab. In some embodiments, the immune checkpoint inhibitor is a CTLA-4 inhibitor, including ipilimumab and / or tesimimab. In some embodiments, the immune checkpoint inhibitor is a LAG-3 inhibitor, including piracetamab and / or olpdullagra.

[0181] V. Method for preparing the compounds of this application The compounds in this application are commercially available or can be prepared using known synthetic processes from starting materials also available from commercial chemical sources. The selection of a specific process to prepare a given compound of this application is within the capabilities of someone skilled in the art.

[0182] The salts of the compounds in this application are generally formed by dissolving a neutral compound in an inert organic solvent, adding the desired acid or base, and then separating the salt by filtration or other known methods.

[0183] The desired compound salt is formed using standard techniques. For example, a neutral compound is treated with an acid or base in a suitable solvent, and the formed salt is separated by filtration, extraction, or any other suitable method.

[0184] The formation of solvates varies depending on the compound and the solvate. Typically, solvates are formed by dissolving the compound in a suitable solvent and separating the solvate by cooling or using an antisolvent. Solvates are typically dried or azeotropically under ambient conditions. The selection of suitable conditions for the formation of a particular solvate can be made by someone skilled in the art. Examples of suitable solvents are ethanol, water, etc. When water is used as the solvent, the molecule is called a "hydrate". The formation of solvates of the compounds in this application varies depending on the compound and the solvate. Typically, solvates are formed by dissolving the compound in a suitable solvent and separating the solvate by cooling or using an antisolvent. Solvates are typically dried or azeotropically under ambient conditions. The selection of suitable conditions for the formation of a particular solvate can be made by someone skilled in the art.

[0185] The prodrugs of the compounds in this application may be, for example, conventional esters formed with available hydroxyl or carboxyl groups. For example, the available hydroxyl group may be acylated using an activated acid in the presence of a base and optionally in an inert solvent (e.g., a pyridine solution of an acyl chloride), and the available carboxyl group may be converted to an ester by reacting the activated acid with a suitable nucleophile in the presence of an activated acid (e.g., by conversion to an acyl chloride or by using a known acid coupling agent), and generally in the presence of a nonnucleophilic base.

[0186] The product of the method described in this application can be separated by known methods, such as solvent evaporation, filtration, centrifugation, chromatography or other suitable methods.

[0187] Those skilled in the art will recognize that, where the reaction steps of this application can be carried out in a variety of solvents or solvent systems, the reaction steps can also be carried out in a mixture of suitable solvents or solvent systems.

[0188] Example This study discovered a class of microbiome-derived metabolites called hydroxyphenyl propionate (HPP) that enhance tumor immune surveillance in mice and synergize with immune checkpoint blockade (ICB) therapy. HPP molecules act as a broad-spectrum enhancer of innate immune signaling pathways in tumor-associated myeloid cells by promoting the cleavage of the pore-forming protein gasdermin D (GSDMD, a key effector of canonical and atypical inflammasome signaling). HPP-treated myeloid cells secrete increased levels of pro-inflammatory cytokines (IL-1β), thereby promoting NF-κB activity in tumor-infiltrating leukocytes. This resulted in improved function of anti-cancer CD8 T cells in mice, significant tumor regression, and better long-term control of cancer with immune checkpoint therapy. Human peripheral blood mononuclear cells also showed a similar response to HPP treatment. GSDMD cleavage was also associated with a favorable response to ICB therapy in patients with advanced melanoma. In summary, this study discovered a previously unknown microbiome-mediated host anti-tumor immune modulation mechanism that can be altered and used to enhance the efficacy of cancer immunotherapy.

[0189] The following non-limiting embodiments are illustrative of this application: Different microbiomes lead to different tumor immune surveillance capabilities in genetically identical hosts. Studies have shown that inbred C57BL / 6 mice obtained from different laboratories have different microbiomes and different cancer immune surveillance capabilities. JCI Insight 3, e94952 (2018); Science 350, 1084-1089 (2015)). To confirm these observations, mice were obtained from Jackson Laboratory (JAX), Charles River Laboratory (CR), and Tacony Farm (TAC). As expected, principal coordinate analysis (PCoA) and relative abundance plots of fecal samples from 16S amplicon sequencing showed that C57BL / 6 mice obtained from these different repositories were colonized with different microbiomes ( Figure 1 a, b). Compared with previous studies ( JCI Insight 3, e94952 (2018); Science Consistent with 350, 1084-1089 (2015), the Muribauculaceae family, previously known as Bacteroidetes S24-7, was the most abundant bacterial family in the feces of JAX mice. In contrast, Bacteroidetesaceae was the most abundant bacterial family in mice obtained from CR and TAC. To test the effect on cancer immune surveillance, M3-9-M rhabdomyosarcoma (RMS) cells were orally implanted into the gastrocnemius muscle of female mice, and tumor size was monitored over time. Compared with CR or TAC mice, JAX mice showed delayed tumor growth and prolonged overall survival. Figure 1This effect depends on CD8 T cells (cf). Figure 1 g), compared with CR mice, tumors harvested from JAX mice contained a greater number of CD8 T cells (g). Figure 1 h). In a supplemental study, the use of broad-spectrum antibiotics (ABX) to induce gut microbiota dysbiosis, employing a dosage regimen that significantly reduced fecal bacterial abundance without affecting body weight (h). Figure 1 As expected, ABX treatment inhibited the growth of M3-9-M in CR mice, but enhanced tumor growth in JAX mice. Figure 1 These data indicate that the microbiome colonized in CR and TAC mice suppressed anti-cancer immunity, while the microbiome in JAX mice promoted the anti-cancer activity of CD8 T cells.

[0190] However, these data and previous reports using similar methods have several important limitations, including the fact that C57BL / 6 mice from different resource banks are genetically different due to the polymorphism accumulated from decades of isolated inbreeding. Genome Biol. 14, 1-22 (2013); Nature 477, 289-294 (2011); Exp. Anim. 58141-149 (2009)), and ABX treatment, in addition to consuming the microbiome, can also directly affect host biology ( Gut 64, 1732-1743 (2015)). To address these limitations, a genetically identical C57Bl / 6 mouse population was established via vertical transfer, all carrying either the JAX or CR microbiome. This population was termed as having different microbiomes at birth ( d ivergent) complex microbiome ( m The genetic similarity of icrobiome ( i dentical mice (mice) m ice)(IMDM)( Figure 2 a). PCoA of fecal samples obtained by 16S amplicon sequencing showed that microbial transfer from donor mice to IMDM hosts was efficient, stable, and universally representative. Figure 2 Among them, Muribacteraceae is a relatively abundant bacterial family colonizing IMDM-JAX mice, while Bacteroidetes is relatively abundant in IMDM-CR mice. Figure 2 f, g). After establishment, M3-9-M cells were orally implanted into female IMDM-CR and IMDM-JAX mice, and tumor growth over time was monitored (f, g). Figure 2 h). Results compared to donor mice ( Figure 1Consistent with IMDM-CR mice, IMDM-JAX mice showed delayed M3-9-M tumor growth and prolonged overall survival. Figure 2 i, j). This difference was not observed in male mice (i, j). Figure 2 k, l), because the M3-9-M cell line is not immunogenic in male mice (k, l). Sci. Transl. Med. 6, (2014)), unless it is engineered with a model antigen (ovalbumin, OVA) ( Figure 2 (m, n). In summary, these results directly support the idea that different complex microbiomes lead to varying host tumor immune surveillance capabilities, which significantly impact overall tumor control. Consistent with this, the M3-9-M established in IMDM-JAX and IMDM-CR mice... OVA OVA-specific CD8 T cells are more abundant in tumors. Figure 2 o).

[0191] Different microbiomes result in unique metabolomics profiles within the same genetically identical host's TME. It is hypothesized that different compositions of the microbiome produce unique metabolomics signatures within the host tumor, thereby modulating innate anti-tumor immunity. To verify this, implanted M3-9-M and M3-9-M were extracted in situ from female and male IMDM mice 18 days after tumor implantation. OVA RMS tumors. Fecal samples were collected prior to tumor implantation. Non-targeted ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) was used to detect mouse fecal and tumor metabolites using 120 metabolite standards. The fecal and tumor metabolomes of the IMDM-CR mouse cluster were found to differ from those of the IMDM-JAX cluster. Figure 3 ad Figure 4 This indicates that their microbiomes produced unique metabolomes in feces and tumors. Furthermore, ABX was provided to the drinking water of female IMDM-JAX mice two weeks prior to tumor implantation and throughout the experiment. Exposure to ABX altered the clustering patterns of the fecal and tumor metabolomes. Figure 3 (eh), indicating that the overall metabolome composition is modifiable.

[0192] Further analysis of the metabolomics dataset was conducted to determine whether specific metabolites were associated with tumor immune surveillance capabilities. Volcano plots of the fecal and tumor metabolomics revealed that some metabolites were significantly upregulated in the fecal and tumor metabolomics of IMDM-JAX mice. Figure 3 i, j and Figure 4e, f). The study focused on L-glutamine (L-gln) and hydroxyphenyl propionate (HPP) because these two metabolites are consistently present in the metabolomics dataset. The relative levels of L-gln were high in fecal and tumor samples from IMDM-CR mice. Figure 4 g, h; Figure 3 k, l). On the other hand, relatively high levels of HPP were observed in fecal and tumor samples from IMDM-JAX mice, suggesting that HPP metabolites are associated with better tumor immune surveillance capabilities. Figure 3 m,n; Figure 4 i, j). The study also found that ABX significantly reduced the relative levels of HPP metabolites in fecal and tumor samples from IMDM-JAX mice (i, j). Figure 4 (k, l), indicating that ABX-sensitive bacteria produce this metabolite. Next, we investigated which members of the gut microbiome produce the HPP metabolite. Fecal samples from IMDM mice were divided into two equal halves; one half was used for untargeted UHPLC-MS metabolomics analysis, and the other half for 16S amplicon sequencing. The metabolomics and metagenomic datasets were prepared by Melonn Pan. 20 Tool training was used, a computational method for predicting metabolite composition from microbiome sequencing data. This method identified 77 gut bacterial amplicon sequence variants (ASVs) positively correlated with HPP metabolite production, including members of the Muribauraceae family previously associated with enhanced antitumor immunity. JCI Insight 3,e94952 (2018)). These results collectively confirm that different microbiomes lead to altered and unique metabolomics profiles in distant host tumors, and that specific metabolites are associated with antitumor immunity.

[0193] Microbiome-derived metabolite HPP enhances tumor immune surveillance capabilities The effect of HPP treatment on tumor outcomes was evaluated. Both immunogenic and non-immunogenic tumors were treated with commercially available purified HPP metabolites. HPP exists in three positional isoforms: 3,2-HPP, 3,3-HPP, and 3,4-HPP, which are present in animal microbiome samples, including those from humans. Analysis using various techniques did not detect any specific enrichment of HPP isoforms in biosamples from IMDM-JAX mice; therefore, all three HPP isoforms were tested, and in vivo experiments were performed starting with 3,2-HPP. L-gln was used as a control metabolite when necessary. Endotoxin levels in the metabolite solutions used were confirmed to be within acceptable limits. Experiments showed that a dose of 83 mg / kg body weight every 48 hours was appropriate for treating mice without toxicity or weight loss. Figure 5 bh).

[0194] To evaluate the effect of 3,2-HPP on anti-tumor immunity, starting from day 1 post-implantation, in IMDM-CR mice, in situ immunogenic and non-immunogenic tumors were treated with this metabolite or solvent control. Figure 6 a). The study found that 3,2-HPP treatment enhanced the treatment of M3-9-M tumors in female mice and M3-9-M tumors in male mice. OVA Tumor immune surveillance ( Figure 6 b, c). Conversely, non-immunogenic M3-9-M tumors in male mice did not respond to 3,2-HPP treatment ( Figure 6 d). This study was also extended to subcutaneous B16.F10 melanoma tumors in female IMDM-CR mice, which have the potential to elicit an immune response due to the presence of HY-specific antigens. Cell Reports Methods 2, (2022) 3,2-HPP treatment also improved the overall survival rate of these mice. Figure 6 e). Furthermore, treatment with 3,2-HPP initiated seven days after implantation of the immunogenic tumor remained effective in IMDM-CR mice. Figure 5 These findings suggest that 3,2-HPP metabolites have the potential to enhance antitumor immunity in hosts carrying an "immunosuppressive" microbiome.

[0195] Next, the effects of 3,2-HPP on antitumor immunity in microbiome-dysregulated hosts were tested. To achieve this, mice were administered drinking water supplemented with ABX starting two weeks before tumor implantation and continuing until the end of the experiment. Figure 6 f). As expected, ABX reduced immune surveillance of M3-9-M tumors in female IMDM-JAX mice, while enhancing immune surveillance in female IMDM-CR mice. Figure 6 Interestingly, 3,2-HPP treatment improved the overall survival rate of IMDM-JAX mice, offsetting the negative effects of ABX (g, h). Figure 6 g). Conversely, in IMDM-CR mice, the combination of ABX and 3,2-HPP treatment resulted in even higher overall survival than either treatment alone. Figure 6 These findings suggest that 3,2-HPP metabolites can enhance antitumor immunity in microbiome-dysregulated hosts.

[0196] It is hypothesized that treatment with HPP metabolites can enhance tumor-specific CD8 T cells in the tumor microenvironment (TME), thereby improving anti-tumor immunity. To test this hypothesis, the effects of 3,2-HPP treatment on male IMDM-CR mice M3-9-M were evaluated. OVA Effects of OVA on specific CD8 T cells within tumors ( Figure 6i). Eighteen days after implantation, 3,2-HPP treatment was found to increase the frequency of OVA-specific CD8 T cells in the tumor. Figure 6 This indicates that the activity of tumor-specific CD8 T cells is associated with the therapeutic efficacy of 3,2-HPP. However, the expression of exhaustion markers such as PD1, TIM3, and LAG3 on these T cells did not change significantly. Figure 6 k). To assess the dependence of 3,2-HPP treatment outcomes on CD8 T cell activity, CD8 T cells were depleted using an anti-CD8 neutralizing antibody. Figure 6 l, Figure 5 lp). Depletion of CD8 T cells weakens the efficacy of 3,2-HPP treatment ( Figure 6 This indicates that the CD8 T cell effector function is well-suited for the treatment of this metabolite.

[0197] Due to the CD8 T cell dependence of 3,2-HPP, its efficacy in combination with clinically approved ICBs (e.g., anti-PD-1 and anti-PD-L1) was tested. This study builds upon previous reports showing that M3-9-M tumors responded to anti-PD-1 therapy and B16.F10 tumors responded to anti-PD-L1 therapy. Sci.Transl.Med. 6, (2014); Mol.Ther. 25, (2017)). Using IMDM-CR female mice implanted with M3-9-M or B16.F10 tumors, it was found that while anti-PD-1 and anti-PD-L1 therapy alone improved the overall survival rate of mice, the combination of 3,2-HPP and these ICB therapies brought further improvement ( Figure 6 This demonstrates the potential of 3,2-HPP to enhance the efficacy of ICB therapy.

[0198] These findings demonstrate that microbiome-derived HPP metabolites can enhance the host's tumor immune surveillance capabilities. Combining these metabolites with other cancer therapies holds promise as a strategy to improve treatment outcomes.

[0199] HPP enhances anti-tumor immunity by strengthening cancer immune signaling pathways in the tumor microenvironment (TME). It is hypothesized that HPP metabolites can enhance antitumor immunity by modulating cancer immune signaling pathways in the tumor microenvironment (TME). To verify this, single-cell RNA sequencing (scRNAseq) was used to analyze M3-9-M cells grown in male IMDM-JAX, IMDM-CR, and IMDM-CR mice (IMDM-CR-HPP) treated with 3,2-HPP. OVAGene expression in immune cells isolated from RMS tumors was identified. Fourteen distinct immune cell clusters were identified, including B cells, regulatory T cells (Tregs), plasmacytoid dendritic cells (pDCs), CD8 T cells, CD4 T cells, natural killer cells (NK cells), NK T cells, CD34+ cells, classical dendritic cells (cDCs), atypical antigen-presenting cells (aAPCs), M1-like and M2-like macrophages, monocyte-myeloid-derived suppressor cells (M-MDSCs), and polymorphonuclear MDSCs (M-MDSCs). Figure 7 ac).

[0200] Wilcoxon rank-sum tests were performed to compare gene expression between IMDM-CR and IMDM-JAX, and between IMDM-CR and IMDM-CR-HPP. These findings suggest that 3,2-HPP treatment has a similar effect on gene expression levels across multiple immune cell types as the JAX microbiome. Figure 7 d). Circos plots of CD8 T cells, PMN-MDSCs, M-MDSCs, M1-like macrophages, aAPCs, and NKT cells showed that many genes affected by 3,2-HPP treatment were also involved in the same pathways as those involved by genes affected by the JAX microbiome. Figure 8 ). Combinatorial circos diagram ( Figure 7 (e) This further highlights the similarities between the effects of 3,2-HPP treatment and the JAX microbiome. Using the Metascape TRRUST database, transcriptional regulators influencing gene expression affecting 3,2-HPP were predicted. Several key regulators involved in cancer immune pathways, such as NF-κB and IRF, were identified. Figure 7 f).

[0201] RAW-Dual in mouse macrophage-like cells TM Reporter cells and human monocytes THP1-Dual TM In reporter cells, the effects of all three HPP metabolites on the activation of two cancer immune signaling pathways, NF-κB and IRF, were validated. The results showed that HPP metabolites alone did not activate NF-κB and IRF signaling in either cell type. However, when used in combination with PRR agonists such as lipopolysaccharide (LPS) and vesicular stomatitis virus (VSV), HPP metabolites significantly enhanced the activation of these pathways. Figure 7 g; Figure 9 Conversely, another metabolite, L-gln, has no effect on the NF-κB or IRF pathways. Figure 9These findings suggest that HPP metabolites act as broad accelerators of the NF-κB and IRF signaling pathways when the immune response initiates these pathways.

[0202] Because different effects of HPP metabolites on the NF-κB and IRF pathways were observed in cell culture, their effects on mouse tumor immune surveillance were tested. HPP treatment was administered one day after orthotopic tumor implantation in IMDM-CR mice, and non-immunogenic M3-9-M showed no response to any HPP metabolite. Figure 7 j). However, all three HPP metabolites enhanced the response to M3-9-M. OVA Immune surveillance of RMS and B16.F10 melanoma ( Figure 7 In summary, these results suggest that HPP metabolites can enhance antitumor immunity by strengthening cancer immune signaling pathways initiated by innate tumor immune surveillance.

[0203] The efficacy of the HPP metabolite analogues in this application against human monocytes THP1-Dual cells was also verified. TM Effects of LPS on NF-κB pathway activation in cells. Exemplary compounds II-1, II-2, II-3, II-4, I-4, I-5, I-6, I-7, III-1, III-2, and IV significantly enhanced NF-κB pathway activation upon treatment with LPS. Figure 15-18 These findings further confirm that HPP metabolites and their analogues act as broad accelerators of NF-κB signaling when the immune response initiates the NF-κB signaling pathway.

[0204] HPP enhances NF- through combination with GSDMD. κ B signaling and anti-tumor immunity It is hypothesized that HPP metabolites enhance cancer immunity by targeting key signaling proteins involved in the NF-κB pathway. This is based on the finding that HPP enhances human THP1-Dual... TM NF-κB induction in cells ( Figure 10 Therefore, thermal proteomic sequencing (TPP) was performed to identify the molecular target of this metabolite. Nonparametric analysis (NPARC) of the response curves was then conducted. Mol. Cell. 18, (2019)), identified 647 potential protein targets of 3,2-HPP metabolites ( Figure 10 b). To narrow the scope of the study, the focus was on GSDMD ( Figure 10 (c, d) GSDMD is a cell membrane pore-forming protein that plays a key role in the inflammasome pathway, IL-1β release, and tumor immunity. Cell Rep. 34, (2021); Cell Res. 25, 1285-98 (2015); J. Immunother Cancer 10, (2022); Cell Rep. 41, (2022); Int. Immunopharmacol. 74, (2019); J. Dig. Dis. 19, (2018); Int. J. Biol. Sci. 17, (2021); Nat. Commun. 13, 1-20 (2022); BMC Cancer 20, (2020); Oncogene 41, 5092-5106 (2022)). Correlation was observed between the expression of inflammasome genes, GSDMD, and NF-κB1 in tumor-infiltrating immune cells. Figure 11 By using M3-9-M OVA RMS was orthotopically implanted into the gastrocnemius muscle of male C57BL / 6NJ (WT) and C57BL / 6N-Gsdmdem4Fcw / J (KO) mice to verify whether 3,2-HPP targets GSDMD-mediated antitumor immunity. Figure 10 e). 3,2-HPP treatment reduced tumor growth and improved overall survival in WT mice, but had no effect on tumors implanted in KO mice. Figure 10 f, g). The study also found that 3,2-HPP treatment affected the secretion of several GSDMD-regulated cytokines, including a significant increase in IL-1β release (f, g). Figure 12 ).

[0205] It was hypothesized that HPP-GSDMD interaction facilitates the secretion of specific cytokines such as IL-1β, which then triggers NF-κB induction via IL-1 receptor signaling. To verify this, wild-type (WT) and GSDMD knockout (KO) THP1 cells were treated with LPS in the presence of HPP molecules and IL-1 neutralizing antibody. After 16 hours, supernatants from KO and WT cells were collected and treated with IL-1 neutralizing antibody. The results showed that the supernatant inhibited THP1-Dual... TM NF-κB induction in reporter cells ( Figure 13 a). In addition, HEK-Blue was also used in the presence of solvent or HPP molecules. TM The effect of LPS-treated supernatant from WT and KOTHP1 cells on IL-1 receptor signaling was evaluated using IL-1β cells. Supernatant collected 16 hours after HPP treatment of WT cells enhanced HEK-Blue in the presence of HPP molecules. TM IL-1 receptor signaling in IL-1β cells ( Figure 13 b; Figure 10 Further analysis of the supernatant revealed that the presence of HPP molecules increased the release of IL-1α and IL-1β from WT cells (h). Figure 13 cd). Assessment of lactate dehydrogenase (LDH) release, an indicator of cell death, showed no significant changes after treatment with LPS or HPP alone or in combination. Figure 13 e).

[0206] In a supplementary study, HPP-GSDMD interaction in THP1 cells was examined using LPS and Nigerian nigerin (NG) stimulation. The results showed that early IL-1 secretion depended on GSDMD activity, as HEK-Blue... TM IL-1β cells responded to the early supernatant of LPS+NG-treated WT cells, but did not respond to the supernatant of GSDMD-KO cells. Figure 13 f). However, prolonged LPS+NG-induced IL-1 secretion was independent of GSDMD activity, as similar responses were observed in the late supernatant from WT and KO cells (f). Figure 10 i). In this case, HPP treatment enhanced IL-1 release from WT cells while preventing LDH release (i). Figure 10 i; Figure 13 Furthermore, the HPP isomer alone does not induce GSDMD cleavage, but the cleavage is enhanced in the presence of LPS or LPS+NG stimulation (g, h). Figure 10 These results indicate that HPP molecules enhance GSDMD activity in a unique way, promoting the release of specific NF-κB-induced cytokines while preventing cell death. The effect of HPP-GSDMD interaction on IRF pathway induction was also assessed. WT and KO cells were treated with VSV in the presence of HPP molecules, and the supernatant was collected 16 hours later using HEK-Blue. TM IRF induction was assessed in IFN-α / β cells via IFN-α / β receptor signaling. Supernatants from HPP-treated WT and KO cells showed enhanced HEK-Blue activity. TM IFN-α / β cell response ( Figure 13 i), which indicates that HPP promotes this pathway in a way that is independent of GSDMD.

[0207] Peptide quantification was performed using publicly available proteomic profiles of stage IV melanoma patients who received tumor-infiltrating lymphocyte (TIL)-based or anti-PD-1 therapy to examine the clinical relevance of GSDMD cleavage. Cell 179, (2019)Although data from the TIL cohort were not helpful in assessing protein cleavage, there was a decrease in cleaved peptides in responders to anti-PD-1 therapy. Caspases cleave human GSDMD protein at residue D275 after the FLTD motif, leading to membrane localization of the N-terminal domain and pore formation. Nature 526, (2015); Proc . Natl.Acad.Sci. 115, (2018)). Therefore, the reduction in uncleaved peptides in responders suggests that enhanced GSDMD cleavage is associated with a good response to anti-PD-1 therapy ( ). Figure 10 To transfer the effects of HPP metabolites to human primary peripheral blood mononuclear cells (huPBMCs), huPBMCs were first treated with LPS in the presence of HPP molecules, followed by NG treatment for 16 hours, and the supernatant was collected for cytokine assessment. HPP molecules enhanced the release of IL-1α and IL-1β (k). Figure 13 (j, k). Furthermore, HPP-treated huPBMCs supernatant enhanced HEK-Blue. TM IL-1β reporter cell response ( Figure 10 k), and protect huPBMCs from LDH release ( Figure 10 In summary, the results indicate that HPP metabolites have a unique effect on GSDMD activity in myeloid cells. They can enhance the release of certain cytokines that activate the NF-κB pathway, thereby improving anti-tumor immunity. Figure 10 ).

[0208] discuss This study investigated the impact of complex microbiomes on tumor immune surveillance in genetically identical hosts. To this end, a self-bred inbred mouse model called IMDM was used, which mimics the natural process of colonization and stabilization of complex microbiomes in genetically identical hosts. This allowed for the determination of causal effects of the microbiome. These findings suggest that colonization of different complex microbiomes in genetically identical hosts produces unique metabolomics profiles, leading to different tumor immune surveillance capabilities. Different microbiome-derived metabolites are associated with enhanced antitumor immune responses and immunotherapy. Science 369, 1481-1489 (2020); Nat. Metab. 2, (2020); Cell Metab. 34, (2022); Cancer Discov. 12, (2022); Sci. Immunol. 7, (2022).; Sci.Immunol. 8, (2023); Cell184, (2021)). For example, studies have shown that specific microbiome-derived metabolites can trigger or enhance the type 1 interferon pathway in mononuclear phagocytes, thereby improving anti-tumor immune responses ( ). Sci. Immunol. 7, (2022); Sci. Immunol. 8, (2023); Cell 184, (2021)). Studies have demonstrated that microbiome-derived HPP metabolites can be used in combination with ICBs to improve therapeutic efficacy in hosts containing diverse microbiomes, including those with dysbiosis. Furthermore, studies have shown that HPP can broadly enhance innate immune signaling pathways, such as the NF-κB and IRF pathways in myeloid cells, and enhance CD8 T cell-dependent tumor clearance.

[0209] Similar to inflammation, GSDMD proteins may act as a double-edged sword in tumor immunity. While some reports suggest that GSDMD may limit anti-tumor immunity during ICB treatment (…),… J. Immunother Cancer 10, (2022); Cell Rep. 41, (2022)), and some also believe that its activation can enhance anti-tumor immunity and effector CD8 T cell responses ( Int.Immunopharmacol. 74, (2019); J. Dig.Dis. 19, (2018); Int. J. Biol. Sci. 17, (2021); Nat . Commun. 13, 1-20 (2022); BMC Cancer 20, (2020); Oncogene 41,5092-5106 (2022)). GSDMD proteins are involved in various molecular functions, including the release of pro-inflammatory cytokines with or without cell death. Nature 526, (2015); Immunity 48, (2018)), mucin secretion by intestinal goblet cells ( Sci. Immunol. 7, (2022)), and nuclear translocation that interferes with the DNA damage repair capacity of PARP-133. Enhanced GSDMD cleavage was found to be associated with a good response to ICB therapy in a group of advanced melanoma patients. In addition, studies have shown that HPP molecules can accelerate GSDMD cleavage while partially preventing cell death and enhancing the NF-κB pathway by promoting the release of pro-inflammatory cytokines such as IL-1α and IL-1β. Other studies have shown that IL-1β can enhance the expansion, function and anti-tumor immunity of CD8 T cells ( Sci.Immunol. 6, (2021); J. Exp.Med.210, 491-502 (2013). The study also found that HPP metabolites can enhance the release of IL-1β from the tumor stroma and the accumulation of tumor-specific CD8 T cells in the TME, thereby improving anti-tumor immunity. In summary, this study demonstrates that microbiome-derived HPP metabolites can enhance the host's tumor immune surveillance capabilities and can be used as adjuvants in various scenarios. Furthermore, some of these findings have been validated in human cells.

[0210] Materials and Methods Cell culture M3-9-M cells were provided by Crystal MacKall (Stanford, CA, USA). M3-9-M cells were transfected with the superpiggyBac transposase expression vector (System Biosciences; Palo Alto, CA, USA) to generate M3-9-M cells. OVA Cells. The American Type Culture Collection (ATCC; Manassas, VA, USA) provided B16.F10 (CRL-6475) and THP-1 (TIB-202). TM ) cells. InvivoGen (San Diego, CA, USA) provides RAW-Dual TM Cells, THP1-Dual TM Cells, HEK-Blue TM IL-1β cells, THP1-Null2 cells, and THP1-KO-GSDMD cells. M3-9-M and M3-9-M OVA Cells were supplemented with 10% heat-inactivated fetal bovine serum (FBS; Life Technologies) and 50 μM 2-mercaptoethanol (Gibco). TM Propagation and culture were carried out in RPMI 1640 (Life Technologies, Carlsbad, CA, USA). This was done to maintain the transgenic M3-9-M... OVA Cells were added to the culture medium at a rate of 1 μg / mL puromycin dihydrochloride (Gibco) every other cell passage. TM B16.F10 (CRL-6475) cells were proliferated and cultured in DMEM (Life Technologies) containing 10% heat-inactivated FBS (Life Technologies).

[0211] RAW-Dual TM Cells and HEK-Blue TMIL-1β cells were cultured in DMEM (Life Technologies), 4.5 g / L glucose, 2 mM L-glutamine, 10% heat-inactivated FBS, and 100 μg / ml Normocin. TM The cells were proliferated and cultured in penicillin-streptomycin (100 U / mL - 100 μg / mL). To maintain the transgenic cell line, 200 μg / mL and 100 μg / mL Zeocin were added to the growth medium at every passage. TM THP-1 (TIB-202) TM THP1-Null2 cells, THP1-Dual TM THP1-KO-GSDMD cells were subjected to RPMI 1640, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated FBS, and 100 μg / ml Normocin. TM Proliferate and culture in penicillin-streptomycin (100 U / mL - 100 μg / mL). To maintain THP1-Dual TM Cells were treated with 10 μg / mL blasticidin and 100 μg / mL zeocin added to the growth medium at each passage. TM To maintain THP1-KO-GSDMD and THP1-HMGB1-Lucia TM Cells were treated with 100 μg / mL Zeocin added to the growth medium at each passage. TM Cryopreservation solutions were prepared for each cell line. Cells were resuspended in growth medium containing 20% ​​FBS and 10% DMSO for storage. All cell lines were screened for mycoplasma every 8–12 weeks using a Thermo Scientific PCR mycoplasma detection kit.

[0212] animal models All animal experiments were conducted in accordance with the Canadian Animal Care Council guidelines and protocols approved by the University of Calgary (Canada) Health Sciences Animal Care Council (AC20-0208 and AC20-0146). Animal experiments involving complex microbiomes were conducted in the University of Calgary's biohazard facility. SPF C57BL / 6J, C57BL / 6NCr, and C57BL / 6NTac mice were sourced from three different commercial vendors: Jackson Laboratories (breeding room RB08), Charles River Laboratory Inc. (breeding room C62), and Taconic Farm (breeding room IBU1501C). GF mice were supplied by the International Microbiome Centre (IMC; University of Calgary) to produce genetically identical mice (IMDM) colonized with different complex microbiomes at birth. The IMDM model was generated through co-hospitalization and breeding in isolated cages within the biohazard facility. Aseptic techniques were followed to avoid microbiome cross-contamination. Microbiome consistency across experiments was confirmed by 16S amplicon sequencing of fecal samples. Mice of different ages and sexes were randomly selected for different experimental groups. GSDMD knockout (KO) mice and wild-type control (WT) mice were obtained from the Jackson Laboratory.

[0213] Cancer model Tumor cells were orally implanted into 6-8 week old mice. Prior to implantation, representative tumor cell lines were tested and found to be negative for common laboratory animal pathogens (Charles River). For the rhabdomyosarcoma model experiment, 1.5 × 10⁻⁶ tumor cells were injected into 50 µL of PBS solution using an insulin syringe. 5 M3-9-M or M3-9-M OVA Cells were orthotopically implanted into the gastrocnemius muscle of the right hind leg of mice. The RMS tumor volume was calculated by subtracting the pre-tumor volume (length × width × height) of the gastrocnemius muscle after tumor implantation. 5 × 10⁵ cells were injected into 50 µL of PBS using an insulin syringe. 5 One B16.F10 melanoma tumor cell was implanted into the right groin of a mouse. The volume of the melanoma tumor was determined by measuring the area (length × width) of the implantation site. 2 The value was determined by (×0.5). From the day of implantation until the experimental or humanitarian endpoint, the tumor was measured twice a week using skin calipers.

[0214] Microbiome composition analysis Gently restrain the mouse and collect the fecal sample directly into a microcentrifuge tube. Store the fecal sample at -80°C for later use. Use the DNeasy PowerSoil Pro Kit (Qiagen). TM Microbial DNA was extracted and purified from fecal samples. The DNA concentration of all samples was adjusted to 25 ng / µL and sent to the Center for Health Genomics and Informatics (CHGI; University of Calgary) for sequencing. At CHGI, the following procedures were performed: preparation of 16S V3-V4 rRNA gene amplicon libraries; Kapa qPCR library quantification analysis (Roche); and 600 Cycle MiSeq v3 sequencing (Illumina). The DADA2 R software package was used for sequencing. Nat. Methods 13, 581 (2016) The sequencing files were processed, and amplicon sequence variants (ASVs) were identified. ASVs were classified using the SILVA53 version 138 reference database maintained by DADA2. The phyloseq R package was used ( PLoS One 8, (2013) The abundance and enrichment, distance, and order of bacteria were determined. Permutational multivariate analysis of variance (PERMANOVA) was performed using the "pairwise.adonis" function (R package version 0.4.(2020)) with 999 permutations, and Bonferroni correction was applied to the multivariate analysis.

[0215] UHPLC-MS non-targeted metabolomics After collection, quick-frozen fecal, serum, and tumor samples were stored at -80°C. On the day of metabolite extraction, 20 mg of fecal or tumor fragments or 20 µL of serum samples were thawed on ice and then extracted with ice-cold 50% methanol (1:50 dilution). Fecal and tumor samples were homogenized by bead milling, incubated on ice for 30 minutes, and then centrifuged at 21000×g for 10 minutes at 4°C. Half of the supernatant was collected and centrifuged again. Finally, 250 µL of supernatant collected from each sample was analyzed by mass spectrometry at the Calgary Metabolomics Research Institute (CMRF; University of Calgary) using Q Exactive... TM Ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) was performed on an HF mass spectrometer (Thermo Scientific) in negative ion full scan mode (50-750 m / z) at a resolution of 240,000. To separate metabolites by UHPLC, a binary solvent mixture was used: 20 mM ammonium formate in LC-MS grade water at pH 3.0 (solvent A) and 0.1% formic acid (%v / v) in LC-MS grade acetonitrile (solvent B), in conjunction with Syncronis... TMColumn (Thermo Fisher Scientific). Run the sample at a flow rate of 600 µL / min using the following gradients: 0–2 min, 100% B; 2–7 min, 100–80% B; 7–10 min, 80–5% B; 10–12 min, 5% B; 12–13 min, 5–100% B; 13–15 min, 100% B. XCMS and MAVEN software packages (… Anal. Chem. 84, 5035 (2012); Curr. Protoc. Bioinformatics Preliminary analysis was performed using 14 (2012), and metabolites were identified by matching m / z signals and retention times with commercial standards. Further statistical significance analysis of the data was conducted using MetaboAnalyst v.5.0. Nat . Protoc. 17, 1735-1761 (2022)).

[0216] Identifying bacteria that produce specific metabolites in the same biological sample Fecal samples were collected from six IMDM-CR and six IMDM-JAX female C57BL / 6 mice. Each sample was divided into two parts: one part was subjected to untargeted metabolomics analysis by UHPLC-MS at CMRF, and the other part was subjected to 16S amplicon sequencing at CHGI. After filtering the initial metagenomic and metabolomics data, the samples were analyzed using the MelonnPan R software package. ( Nat. Commun. 10, 1-11 (2019)) to identify bacteria that produce HPP metabolites. Paired sequence feature tables and microbial community metabolite abundances are used as inputs to the "melonnnpan.train" function, which allows for unbiased identification of specific bacteria that produce metabolites in the same biological sample.

[0217] Antibiotic-mediated dysbiosis A broad-spectrum antibiotic mixture consisting of ampicillin (1 mg / mL), neomycin (1 mg / mL), vancomycin (0.5 mg / mL), and metronidazole (1 mg / mL) was added to the drinking water of mice. The metronidazole concentration was gradually increased, reaching 1 mg / mL on day 9. Antibiotic treatment began two weeks before tumor inoculation and continued throughout the experiment, with the antibiotic-supplemented drinking water replaced every 3–4 days. The health status of the mice was monitored by measuring their body weight. To assess the effectiveness of the antibiotics, universal oligonucleotide primers (forward primer, 5μm) targeting the conserved region of the eubacterial 16S rRNA gene were used. 1320 -CCATGAAGTCGGAATCGCTAG- 13413ʹ; reverse primer, 5ʹ 1431 -ACTCCCATGGTGTGACGG- 1413 Real-time polymerase chain reaction (RT-PCR) was performed on fecal microbial DNA using the DNeasy PowerSoil Pro Kit (Qiagen). TM Extract fecal microbial DNA and use iQ TM SYBR® Green supermix (Bio-Rad), 300 nM of each primer, 3 ng of DNA template, and UltraPure TM DNase / RNase-Free Distilled Water (Invitrogen) TM Prepare 20 µL of PCR reaction mixture. Use Bio-Rad® CFX96. TM The RT-PCR system was thermally cycled. The activation and denaturation process of the polymerase was as follows: 95℃ for 5 minutes, followed by 35 cycles of denaturation at 95℃ for 15 seconds, annealing at 60℃, and extension for 1 minute.

[0218] Flow cytometry Tumors were isolated from mice using a mouse tumor dissociation kit (Miltenyi Biotec) according to the manufacturer's instructions, and single-cell suspensions were prepared. The isolated tumors were cut into small pieces with a diameter of ~2-4 mm using a sterile scalpel. The tumor samples were homogenized for 1 minute in RPMI 1640 medium and enzyme mixture, and the homogenate was incubated at 37°C with gentle shaking for 40 minutes. The homogenate was then filtered through a 70 µm cell filter and centrifuged to obtain the single-cell suspension. Red blood cells (RBCs) were removed using red blood cell lysis buffer. White blood cell separation was performed using a Percoll gradient, followed by staining of live and dead cells with Zombie Aqua dye (BioLegend). T lymphocytes were stained with anti-CD4-FITC (clone RM4-4, BioLegend), anti-CD8-PE.Cy7 (clone 53-6.7, BioLegend), anti-CD3-BV421 (clone 145-2C11, BioLegend), anti-CD45-APC.Cy7 (clone 30-F11, BioLegend), anti-PD-1-FITC (clone 29F.1A12, BioLegend), anti-TIM3-PE (clone RMT3-23, BioLegend), and anti-LAG3-PerCP / Cy5.5 (clone C9B7W, BioLegend) to stain for cell surface markers. For the detection of OVA-specific CD8 T cells, a tetramer labeled with human B2M SIINFEKL Alexa 647 was used from H-2K(b) chicken eggs 257-264. Cells were stained, washed with FACS buffer, and quantified using an Attune NxT flow cytometer (Thermo Fisher Scientific).

[0219] mouse treatment regimen The metabolite compounds were derived from Sigma-Aldrich by dissolving them in UltraPure containing 1.0N NaOH (Sigma). TM DNase / RNase-Free Distilled Water (Invitrogen) TMMetabolite stock solutions were prepared using [a specific method / method - details needed]. The pH of the stock solutions was adjusted to 7.4–7.6, and endotoxin levels in the solutions were determined using the Limulus Amebocyte Lysate (LAL) assay. First, the maximum tolerated dose and pharmacokinetics of the metabolite for animal experiments were determined. To test the effect of the metabolite on antitumor immunity, each mouse was intraperitoneally injected with 100 µL of the metabolite at a dose of 83 mg / kg body weight, every 48 hours for a total of 7 injections. In the immune checkpoint blockade (ICB) assay, anti-PD-1 (clone RMP1-14, BioXcell) and anti-PD-L1 (clone 10F.9G2, BioXcell) antibodies were used. Three doses of 250 µg of anti-PD-1 or anti-PD-L1 were intraperitoneally injected on days 10, 13, and 16 post-tumor implantation. An anti-CD8 (clone 2.43; BioXcell) monoclonal antibody was used to neutralize CD8 T cells in mice. Seven days and one day before tumor implantation, each mouse was intraperitoneally injected with 250 μg of anti-CD8 antibody in PBS, followed by injections of 100 μg of anti-CD8 antibody in PBS on days 3, 7, and 10. The efficiency of T cell exhaustion was monitored by flow cytometry using anti-CD8-PE.Cy7 antibody (clone 53-6.7, BioLegend).

[0220] NF-κB and IRF activity reporter assay Using mice RAW-Dual TM (InvivoGen) and THP1-Dual TM (InvivoGen) reporter cell lines were used for NF-κB and IRF induction assays. Cells were resuspended in freshly prepared test medium, RAW-Dual. TM The cell concentration was 1.0 × 10⁻⁶. 6 cells / mL, THP1-Dual TM The cell concentration was 5.0 × 10⁻⁶. 5 Cells / mL. 180 µL of cells were seeded per well in a standard 96-well plate, and the concentrations of several PRR agonists that trigger NF-κB and IRF were optimized. To test the effects of metabolites on these pathways, 10 µL of the optimized receptor agonist and 10 µL of 2 mM metabolite solution or solvent were added to each well to bring the final volume to 200 µL. To neutralize IL-1 receptor signaling, anti-IL-1α (clone 7D4, InvivoGen) and anti-IL-1β (clone 4H5, InvivoGen) antibodies were added according to the manufacturer's recommendations, with IgG1 isotype (clone T8E5, InvivoGen) used as a control. QUANTI-Blue was used. TMThe activity of NF-κB was determined by measuring the level of secreted embryonic alkaline phosphatase (SEAP) in a solution (InvivoGen). 20 µL of cell culture supernatant was aliquoted into 180 µL of QUANTI-Blue. TM Afterward, the color transition to blue was monitored, and SEAP levels were measured at 650 nm using a Molecular Devices SpectraMax i3. To assess IRF induction, QUANTI-Luc was used. TM The level of secreted luciferase in the culture medium was measured using the InvivoGen solution. 20 µL of cell culture supernatant was aliquoted into 50 µL of QUANTI-Luc... TM In the solution, the luminescence readings were immediately recorded using a SpectraMax i3.

[0221] Cell viability and cytotoxicity assays Using AlamarBlue TM (Invitrogen) TM Cell viability and cytotoxicity were assessed using Roche's Cytotoxicity Detection Kit PLUS (LDH). For cell viability, 10 μL of alamarBlue was added to each well of a 96-well plate. TM Mix with 90 μL of cell culture per well, incubate at 37°C and 5% CO2, and read fluorescence using a SpectraMax i3. Cell-containing medium serves as a positive control, and cell-free medium as a negative control. For LDH release assay, mix 46 μL of reaction mixture with 46 μL of cell culture supernatant in a 96-well plate and incubate in the dark for 20 minutes. Read using a SpectraMax i3. The positive control is cell supernatant treated with lysis buffer, and the negative control is cell-free medium.

[0222] Cytokine detection With 0.5-1.0×10 6 Cells were seeded into 96-well plates at a density of 1 cell / well and then treated with a PRR agonist, with or without a metabolite. Culture supernatant was collected at specific time points to measure cytokine levels. Samples were prepared according to the protocol described by Kim et al. to detect cytokine levels in tumor stroma fluid. Nat . Commun. 8, (2017)). HEK-Blue was incubated with the collected culture supernatant. TM IL-1β cells (Invitrogen) TM ), and with QUANTI-Blue TMSolution (Invitrogen) TM The SEAP level in the culture medium was measured to determine the cellular IL-1 level. This was also performed using Luminex technology from Eve Technologies (Calgary, Alberta). TM The 200 system (Luminex, Austin, TX, USA) was used for multiplex quantification of cytokines, chemokines, and growth factors.

[0223] Single-cell RNA sequencing (scRNAseq) M3-9-M OVA RMS cells were in situ seeded into male IMDM mice, and the 3,2-HPP treatment regimen was initiated one day after tumor implantation. Six hours before tumor extraction, the final treatment dose was administered to assess its impact on early gene expression in the context of an overall survival study. Fourteen days later, tumors were extracted using a sterile scalpel and cut into small pieces (~2-4 mm in diameter), and single-cell suspensions were prepared using a tumor dissociation kit (Miltenyi Biotec). Viable cell density was enriched using a dead cell removal kit (Miltenyi Biotec), and CD45+ tumor-infiltrating immune cells were isolated using mouse CD45 (TIL) microbeads (Miltenyi Biotec). Flow cytometry was used to verify the purity of the isolated CD45+ cell population (average 95%), and cell health was confirmed by microscopy. Two samples were then pooled from each experimental group to enrich the number of cells used for constructing scRNA libraries. The Chromium Single Cell 3ʹ GEM (Library and Gel Bead Kit v3) and Chromium Controller platform were used to construct scRNA libraries, aiming for approximately 5000 cells per library. Then, NovaSeq was used at CHGI (University of Calgary). TM The 6000 platform (Illumina) was used to sequence the library, with a single flow cell targeting 100,000 reads per cell.

[0224] scRNAseq data analysis Raw sequencing files were processed using Cell Ranger 6.0.2 (10x Genomics). The raw base call (BCL) files were demultiplexed into FASTQ files (sample indices: IMDM-CR = SI-GA-A3, IMDM-CR-HPP = SI-GA-B3, and IMDM-JAX = SI-GA-C3) using the "cellranger count" pipeline. Sequence alignment, filtering, barcode counting, UMI counting, and mapping to a pre-constructed mouse reference genome in 10xGenomics (mm10, GENCODE vM23 / Ensembl 98, July 7, 2020) were performed using the "cellranger aggr" pipeline. Libraries were aggregated at the same sequencing depth for analysis in Loupe Browser 5.1.0. Data were also analyzed using Seurat R packages 60-62, with results consistent with Loupe Browser analysis. Data was filtered, samples were integrated, genes were normalized, dimensionality was reduced, and data was visualized using Seurat. Cells with too few or too many features (<200 or >7500) and high mitochondrial gene frequencies (>5%) were removed. All samples were integrated into a single Seurat object, and the data was scaled, linearly and non-linearly reduced in dimensionality, and cells were clustered. Manual annotation was performed using cell type-specific expression markers. Nature 562, 367-372 (2018); Nat. Commun. 11, (2020); Nucleic Acids Res. 51, (2022); J. Immunother Cancer 9, 1-18 (2021); J. Immunother Cancer 10, 1-14 (2022); J. Exp.Med. 218, (2021)). Differentially expressed genes were identified using the Wilcoxon rank-sum test. Metascape ( Nat. Commun. 10, (2019)) and Cytoscape ( Genome Res. 13, (2003)) for pathway identification and protein network visualization.

[0225] Thermal proteomic profiling analysis using intact cells 24 mL THP1-Dual TMCells (density 1.5 x 10⁶ cells / mL) were treated with 2 mM metabolite or solvent control for 16 hours. Cells were then centrifuged at 340 xg for 5 minutes at 4°C, resuspended in 20 mL of ice-cold PBS, and centrifuged again. The cells were resuspended in 1200 µL of PBS, divided into ten 100 µL aliquots into 0.2 mL PCR tubes, and centrifuged at 325 xg for 2 minutes at 4°C. 80 µL of PBS supernatant was removed by pipetting, and the tubes were gently tapped to resuspend the cells. The cell tubes treated with both metabolite and solvent were then heated in parallel in a PCR instrument for 3 minutes at a temperature ranging from 37°C to 67°C. After incubating at room temperature for 3 minutes, the cells were flash-frozen in liquid nitrogen for 1 minute. The cells were briefly thawed in a 25°C water bath, placed on ice, and then resuspended by pipetting. The freeze-thaw cycle was repeated once, and then 30 µL of PBS was added to the sample. Centrifuge all contents at 100,000 xg for 20 minutes at 4°C. Transfer the supernatant to a new tube and measure the protein concentration of the sample at 37°C. Reduce the lysis buffer with 10 mM dithiothreitol (DTT) for 30 minutes at room temperature, then alkylate the lysis buffer with 50 mM chloroacetamide (CAA) for 30 minutes in the dark. Determine the volume of lysis buffer that produces 200 µg of protein at 37°C and transfer it to a new tube for use at all other temperature points.

[0226] Protein cleaning and peptide digestion Proteins were cleaned and peptides were digested according to the previously described method. Science 346, (2014); Nat.Protoc. 10, 1567-1593 (2015)). For each sample, the lysis buffer volume at 37 °C (equivalent to 200 µg) was brought to 190 µL with 50 mM HEPES-NaOH at pH 7.3. SP3 beads (Sera-Mag SpeedBeads, GE Healthcare, cat. no. 41552105050250 and 65152105050250) were washed twice with 180 µL H2O, resuspended in 10 µL H2O, and added to the sample along with 200 µL 100% ethanol. The sample was then incubated for 10 min at 1000 rpm in a thermostat at room temperature. The sample was washed four times with 180 µL of 80% ethanol, and the beads were resuspended in 200 µL of 50 mM HEPES-NaOH solution (pH 7.3) containing 4 µg of trypsin Lys C (Promega). The sample was incubated overnight at 600 rpm on a shaking platform at 37°C. The next day, the digested peptides were transferred to a new eppendorf tube. TMThe peptide concentration was measured in a tube at a temperature of 37°C.

[0227] TMT Marking Add 80 µL of 100% acetonitrile to 0.8 mg TMT reagent. Then, for each sample, select an equal volume of 100 µg peptide from the 37°C temperature point and place it in a new Eppendorf tube. Add 10 µL of TMT label to each sample and incubate at room temperature for 30 min. Add 10 µL of TMT label and repeat this process. Quench the TMT label with 10 µL of 1 M glycine. Then, pool all 10 samples and dry them using a rapid vacuum concentrator. Desalt 50% of the samples using Pierce Peptide Desalting Spin columns (cat.no.89852) and resuspend them in high-pH mobile phase A (20 mM ammonium formate). Fractionate the peptides using high-pH C18 reversed-phase HPLC with mobile phase B (100% ACN), a gradient of 54 min (5%–80% B), and a flow rate of 0.2 mL / min. Combine the 54 fractions into 18 fractions and dry them. Finally, the peptide was resuspended in 20 µL of 0.1% formic acid for mass spectrometry analysis. The NPARC R software package was used for this analysis. Mol. Cell. Proteomics Data analysis was conducted on 18, (2019).

[0228] Protein blot Cells were collected and lysates were prepared using total lysis buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% Triton X-100; 1% SDS). The supernatant was obtained by centrifugation at 10,000 RPM for 10 minutes at 4°C using a benchtop PCR centrifuge. Protein quantification was performed using the Bio-Rad DC Protein Assay Kit (Bio-Rad, NC, USA). Proteins were separated using a 12% SDS-PAGE gel and then transferred to a PVDF membrane for 1 hour using a Bio-Rad Trans-turbo semi-dry transfer instrument at 25 V / 1A. The membrane was then lysed with Tris-buffered saline-Tween-20 containing 5% skim milk. TMThe membrane was blocked at room temperature for 30 minutes using TBST. Then, human FL-GSDMD, CL-GSDMD, and actin on the membrane were detected overnight at 4°C using rabbit monoclonal recombinant anti-GSDMD antibody (ab210070, Abcam), anti-cleaved N-terminal GSDMD antibody (ab215203, Abcam), and mouse anti-actin monoclonal antibody (MAB1501, MilliporeSigma). The next day, the membrane was washed three times with TBST and detected for 1 hour at room temperature using goat anti-rabbit (1706515, Bio-Rad) or goat anti-mouse (1706516, Bio-Rad) horseradish peroxidase-conjugated IgG. Secondary antibody was diluted 1:5000 in TBST containing 5% (w / v) skim milk. The membrane was washed with TBST and then imaged on a Chemidoc-IT Imager (UVP, Upland, CA, USA) using Clarity. TM Western ECL substrate (Bio-Rad) detection of target proteins.

[0229] Determining the sample size and conducting statistical analysis Sample sizes were pre-determined for each experiment, and pre-experiments were conducted to approximate the effect size. The sample size for animal experiments was estimated using the power analysis tool from ClinCalc.com (https: / / clincalc.com / stats / samplesize.aspx). Mice were ensured to be randomly assigned to experimental groups and housed in multiple cages to eliminate cage effects. Prior experience and expert consultation also helped determine sample sizes for certain techniques. All data points were included in the analysis, and tumor growth kinetics, animal survival, and in vitro experimental data were analyzed using GraphPad Prism version 7.0. Statistical significance tests were performed on TPP-TR, scRNAseq, and 16S amplicon sequencing data using the R package. Shapiro-Wilk normality tests or D'Agostino-Pearson comprehensive normality tests were performed to determine the data distribution type. Parametric statistical tests were performed if the values ​​followed a Gaussian or normal distribution; otherwise, nonparametric statistical tests were used. Confidence intervals were set at 95%, and the names and p-values ​​of the statistical tests were reported in the corresponding plot or table labels.

[0230] While this application has been described with reference to examples now considered preferred, it should be understood that this application is not limited to the disclosed examples. Rather, this application is intended to cover various modifications and equivalent arrangements within the spirit and scope of the appended claims.

[0231] All publications, patents, and patent applications are incorporated herein by reference in their entirety to the same extent that each individual publication, patent, or patent application is expressly and individually indicated to be incorporated herein by reference in its entirety. Where a term in this application is found to be defined differently in documents incorporated herein by reference, the definition provided herein shall be used as the definition of that term.

[0232] References Chen, DS & Mellman, I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity 39, 1-10 (2013). Chen, DS & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321-330 (2017). Osipov, A., Saung, MT, Zheng, L. & Murphy, AG Small moleculeimmunomodulation: The tumor microenvironment and overcoming immune escape. Journal for ImmunoTherapy of Cancer 7, (2019). Binnewies, M. et al. Understanding the tumor immune microenvironment(TIME) for effective therapy. Nat. Med. 24, (2018). Barth, H., Fischer, S., Möglich, A. & Förtsch, C. Clostridial C3toxins target monocytes / macrophages and modulate their functions. Frontiers in Immunology 6, (2015). Li, R. et al.Gut microbiota-stimulated cathepsin K secretionmediates TLR4-dependent M2 macrophage polarization and promotes tumormetastasis in colorectal cancer. Cell Death Differ. 26, (2019). Gorjifard, S. & Goldszmid, R. S. Microbiota—myeloid cell crosstalkbeyond the gut. J. Leukoc. Biol. 100, (2016). Roy, S. & Trinchieri, G. Microbiota: A key orchestrator of cancertherapy. Nature Reviews Cancer 17, (2017). Daillère, R. et al. Trial watch: the gut microbiota as a tool toboost the clinical efficacy of anticancer immunotherapy. Oncoimmunology 9, 1-8 (2020). Wang, Y. et al. Fecal microbiota transplantation for refractoryimmune checkpoint inhibitor-associated colitis. Nat. Med. (2018). doi:10.1038 / s41591-018-0238-9 Davar, D. et al. Fecal microbiota transplant overcomes resistance toanti-PD-1 therapy in melanoma patients. Science 371, (2021). Baruch, E. N. et al.Fecal microbiota transplant promotes response inimmunotherapy-refractory melanoma patients. Science 371, (2021). Uribe-Herranz, M. et al. Gut microbiota modulates adoptive celltherapy via CD8α dendritic cells and IL-12. JCI Insight 3, e94952 (2018). Sivan, A. et al. Commensal Bifidobacterium promotes antitumorimmunity and facilitates anti-PD-L1 efficacy. Science 350, 1084-1089 (2015). Simon, M. M. et al. A comparative phenotypic and genomic analysis ofC57BL / 6J and C57BL / 6N mouse strains. Genome Biol. 14, 1-22 (2013). Keane, T. M. et al. Mouse genomic variation and its effect onphenotypes and gene regulation. Nature 477, 289-294 (2011). Mekada, K. et al. Genetic differences among C57BL / 6 substrains. Exp. Anim. 58, 141-149 (2009). Morgun, A. et al. Uncovering effects of antibiotics on the host andmicrobiota using transkingdom gene networks. Gut 64, 1732-1743 (2015). Highfill, S. L. et al. Disruption of CXCR2-mediated MDSC tumortrafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, (2014). Mallick, H. et al. Predictive metabolomic profiling of microbialcommunities using amplicon or metagenomic sequences. Nat. Commun. 10, 1-11(2019). Lyubetskaya, A. et al. Assessment of spatial transcriptomics foroncology discovery. Cell Reports Methods 2, (2022). Durham, N. M. et al. Oncolytic VSV Primes Differential Responses toImmuno-oncology Therapy. Mol. Ther. 25, (2017). Childs, D. et al. Nonparametric Analysis of Thermal Proteome ProfilesReveals Novel Drug-binding Proteins. Molecular, Cellular, and Proteomics 18, (2019). Tsuchiya, K. et al. Gasdermin D mediates the maturation and releaseof IL-1α downstream of inflammasomes. Cell Rep. 34, (2021). He, W. et al.Gasdermin D is an executor of pyroptosis and requiredfor interleukin-1β secretion. Cell Res. 25, 1285-98 (2015). Lv, T. et al. Targeting of GSDMD sensitizes HCC to anti-PD-1 byactivating cGAS pathway and downregulating PD-L1 expression. J. Immunother. Cancer 10, (2022). Jiang, Y. et al. Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade. Cell Rep. 41, (2022). Xi, G. et al. GSDMD is required for effector CD8+ T cell responses tolung cancer cells. Int. Immunopharmacol. 74, (2019). Wang, W. J. et al. Downregulation of gasdermin D promotes gastriccancer proliferation by regulating cell cycle-related proteins. J. Dig. Dis. 19, (2018). Yan, H. et al. Cisplatin induces pyroptosis via activation of meg3 / nlrp3 / caspase-1 / gsdmd pathway in triple-negative breast cancer. Int. J. Biol. Sci. 17, (2021). Ning, H. et al.Enhancer decommissioning by MLL4 ablation elicitsdsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity. Nat. Commun. 13, 1-20 (2022). Yang, Y. et al. Hydrogen inhibits endometrial cancer growth via aROS / NLRP3 / caspase-1 / GSDMD-mediated pyroptotic pathway. BMC Cancer 20, (2020). Peng, X. et al. Nuclear translocation of Gasdermin D sensitizescolorectal cancer to chemotherapy in a pyroptosis-independent manner. Oncogene 41, 5092-5106 (2022). Harel, M. et al. Proteomics of Melanoma Response to ImmunotherapyReveals Mitochondrial Dependence. Cell 179, (2019). Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determinespyroptotic cell death. Nature 526, (2015). Yang, J. et al. Mechanism of gasdermin D recognition by inflammatorycaspases and their inhibition by a gasdermin D-derived peptide inhibitor. Proc. Natl. Acad. Sci. 115, (2018). Mager, L. F. et al. Microbiome-derived inosine modulates response tocheckpoint inhibitor immunotherapy. Science 369, 1481-1489 (2020). Wang, T. et al. Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction. Nat. Metab. 2, (2020). Wang, H. et al. The microbial metabolite trimethylamine N-oxidepromotes antitumor immunity in triple-negative breast cancer. Cell Metab. 34,(2022). Messaoudene, M. et al. A Natural Polyphenol Exerts Antitumor Activityand Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota. Cancer Discov. 12, (2022). Mirji, G. et al. The microbiome-derived metabolite TMAO drives immuneactivation and boosts responses to immune checkpoint blockade in pancreaticcancer. Immunological Science. 7, (2022). Jneid, B. et al. Selective STING stimulation in dendritic cellsprimes antitumor T cell responses. Immunological Science. 8, (2023). Lam, K. C. et al. Microbiota triggers STING-type I IFN-dependentmonocyte reprogramming of the tumor microenvironment. Cell 184, (2021). Steed, A. L. et al. The microbial metabolite desaminotyrosineprotects from influenza through type I interferon. Science 357, 498-502(2017). Wei, Y. et al. The intestinal microbial metabolite desaminotyrosineis an anti-inflammatory molecule that modulates local and systemic immunehomeostasis. FASEB J. 34, 16117-16128 (2020). Zhao, H., Lazarenko, O. P. & Chen, J. R. Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis throughRANKL-RANK independent pathway. J. Cell. Physiol. 235, (2020). Cheng, D. et al. Comparative Study on the Protective Effect ofChlorogenic Acid and 3-(3-Hydroxyphenyl) Propionic Acid against Cadmium-Induced Erythrocyte Cytotoxicity: In Vitro and in Vivo Evaluation. J. Agric. Food Chem. 69, (2021). Evavold, C. L. et al. The Pore-Forming Protein Gasdermin D RegulatesInterleukin-1 Secretion from Living Macrophages. Immunity 48, (2018). Zhang, J. et al. Epithelial Gasdermin D shapes the host-microbialinterface by driving mucus layer formation. Immunological Science. 7, (2022). Han, C. et al. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediatedantitumor effects during radiation. Immunological Science. 6, (2021). Ben-Sasson, S. Z. et al. IL-1 enhances expansion, effector function,tissue localization, and memory response of antigen-specific CD8 T cells. J. Exp. Med. 210, 491-502 (2013). Callahan, B. J. et al. DADA2: High resolution sample inference fromIllumina amplicon data. Nat. Methods 13, 581 (2016). Quast, C. et al. The SILVA ribosomal RNA gene database project:improved data processing and web-based tools. Nucleic Acids Res. 41, (2013). McMurdie, P. J. & Holmes, S. Phyloseq: An R Package for ReproducibleInteractive Analysis and Graphics of Microbiome Census Data. PLoS One 8,(2013). Martinez Arbizu, P. Pairwise multilevel comparison using adonis. Rpackage version 0.4. (2020). Available at: https: / / github.com / pmartinezarbizu / pairwiseAdonis. Tautenhahn, R., Patti, G. J., Rinehart, D. & Siuzdak, G. XCMS Online:a web-based platform to process untargeted metabolomic data. Anal. Chem. 84,5035 (2012). Clasquin, M. F., Melamud, E. & Rabinowitz, J. D. LC-MS DataProcessing with MAVEN: A Metabolomic Analysis and Visualization Engine. Curr. Bioinformatics Protocol 14, (2012). Pang, Z. et al. Using MetaboAnalyst 5.0 for LC-HRMS spectraprocessing, multi-omics integration and covariate adjustment of globalmetabolomics data. Nat. Protoc. 17, 1735-1761 (2022). Kim, D. S. et al.Smac mimetics and oncolytic viruses synergize indriving anticancer T-cell responses through complementary mechanisms. Nat. Common. 8, (2017). Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A.Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495-502 (2015). Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R.Integrating single-cell transcriptomic data across different conditions,technologies, and species. Nat. Biotechnol. 36, 411-420 (2018). Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888-1902 (2019). Schaum, N. et al. Single-cell transcriptomics of 20 mouse organscreates a Tabula Muris. Nature 562, 367-372 (2018). Yao, J. et al. Single-cell transcriptomic analysis in a mouse modeldeciphers cell transition states in the multistep development of esophagealcancer. Nat. Commun. 11, (2020). Hu, C. et al. CellMarker 2.0: an updated database of manually curatedcell markers in human / mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 51, (2022). Zhang, C. et al. Single-cell sequencing reveals antitumorcharacteristics of intratumoral immune cells in old mice. J. Immunother. Cancer 9, 1-18 (2021). Costa, A. et al. Single-cell transcriptomics reveals sharedimmunosuppressive landscapes of mouse and human neuroblastoma. J. Immunother. Cancer 10, 1-14 (2022). Veglia, F. et al. Analysis of classical neutrophils andpolymorphonuclear myeloid-derived suppressor cells in cancer patients andtumor-bearing mice. J. Exp. Med. 218, (2021). Zhou, Y. et al. Metascape provides a biologist-oriented resource forthe analysis of systems-level datasets. Nat. Commun. 10, (2019). Shannon, P. et al.Cytoscape: A Software Environment for IntegratedModels of Biomolecular Interaction Networks. Genome Res. 13, (2003). Savitski, M. M. et al. Tracking cancer drugs in living cells bythermal profiling of the proteome. Science 346, (2014). Franken, H. et al. Thermal proteome profiling for unbiasedidentification of direct and indirect drug targets using multiplexedquantitative mass spectrometry. Nat. Protoc. 10, 1567-1593 (2015).

Claims

1. A method for enhancing antitumor immunity in biological samples or cells of a patient in need, comprising administering to said cells an effective amount of one or more compounds of formula (I) or pharmaceutically acceptable salts, solvates, and / or ester prodrugs thereof: in R 1 R 2 and R 3 It is OH or H independently, provided that R is present. 1 R 2 and R 3 At least one of them is OH.

2. A method for enhancing antitumor immunity, comprising administering to a subject in need a therapeutically effective amount of one or more compounds of formula (I) or pharmaceutically acceptable salts, solvates, and / or ester prodrugs thereof: in R 1 R 2 and R 3 It is OH or H independently, provided that R is present. 1 R 2 and R 3 At least one of them is OH.

3. A method of treating cancer, comprising administering to a subject in need a therapeutically effective amount of one or more compounds of formula (I) or a pharmaceutically acceptable salt, solvate, and / or ester prodrug thereof: in R 1 R 2 and R 3 It is OH or H independently, provided that R is present. 1 R 2 and R 3 At least one of them is OH.

4. The method according to any one of claims 1 to 3, wherein one or more compounds of formula (I) are selected from 3,2-hydroxyphenylpropionate, 3,3-hydroxyphenylpropionate and 3,4-hydroxyphenylpropionate, or pharmaceutically acceptable salts, solvates and / or ester prodrugs thereof.

5. The method according to any one of claims 1 to 3, wherein one or more compounds of formula (I) are selected from sodium 3-(4-hydroxyphenyl)propionate, methyl 3-(4-hydroxyphenyl)propionate, ethyl 3-(4-hydroxyphenyl)propionate and N-hydroxysuccinimide 3-(4-hydroxyphenyl)propionate.

6. A method for enhancing antitumor immunity in biological samples or cells of a patient in need, comprising administering to said cells an effective amount of one or more compounds of formula (II), (III), or (IV) or a pharmaceutically acceptable salt, solvate, and / or ester prodrug thereof: in R 4 Selected from halogens, NR 5 R 6 and C 1-3 Alkyl groups; and R 5 and R 6 Independently selected from H and C 1-3 alkyl; in R 7 It is OH; and n is 3-5; or (IV).

7. A method for enhancing antitumor immunity, comprising administering to a subject in need a therapeutically effective amount of one or more compounds of formula (II), (III), or (IV) or a pharmaceutically acceptable salt, solvate, and / or ester prodrug thereof: in R 4 Selected from halogens, NR 5 R 6 and C 1-3 Alkyl groups; and R 5 and R 6 Independently selected from H and C 1-3 alkyl; in R 7 It is OH; and n is 3-5; or (IV).

8. A method of treating cancer, comprising administering to a subject in need a therapeutically effective amount of one or more compounds of formula (II), (III), or (IV) or a pharmaceutically acceptable salt, solvate, and / or ester prodrug thereof: in R 4 Selected from halogens, NR 5 R 6 and C 1-3 Alkyl groups; and R 5 and R 6 Independently selected from H and C 1-3 alkyl; in R 7 It is OH; and n is 3-5; or (IV).

9. The method according to any one of claims 6 to 9, wherein the compound is selected from: Or a pharmaceutically acceptable salt, solvate, and / or ester prodrug.

10. A method for enhancing antitumor immunity in biological samples or cells of a patient in need, comprising administering to said cells an effective amount of one or more compounds of formula (V) or pharmaceutically acceptable salts, solvates, and / or ester prodrugs thereof: in R 8 R 9 and R 10 It is OH or H independently, provided that R is present. 8 R 9 and R 10 At least one of them is OH, or R 8 R 9 and R 10 One of them is selected from halogen, NR 13 R 14 and C 1-3 Alkyl groups, and R 8 R 9 and R 10 The other two are H; R 13 and R 14 Independently selected from H and C 1-3 alkyl; R 11 Selected from H and =O; R 12 Selected from H, C 1-4 Alkyl and succinimide; and p is 1-4.

11. A method for enhancing antitumor immunity, comprising administering to a subject in need a therapeutically effective amount of one or more compounds of formula (V) or a pharmaceutically acceptable salt, solvate, and / or ester prodrug thereof: in R 8 R 9 and R 10 It is OH or H independently, provided that R is present. 8 R 9 and R 10 At least one of them is OH, or R 8 R 9 and R 10 One of them is selected from halogen, NR 13 R 14 and C 1-3 Alkyl groups, and R 8 R 9 and R 10 The other two are H; R 13 and R 14 Independently selected from H and C 1-3 alkyl; R 11 Selected from H and =O; R 12 Selected from H, C 1-4 Alkyl and succinimide; and p is 1-4.

12. A method of treating cancer, comprising administering to a subject in need a therapeutically effective amount of one or more compounds of formula (V) or a pharmaceutically acceptable salt, solvate, and / or ester prodrug thereof: in R 8 R 9 and R 10 It is OH or H independently, provided that R is present. 8 R 9 and R 10 At least one of them is OH, or R 8 R 9 and R 10 One of them is selected from halogen, NR 13 R 14 and C 1-3 Alkyl groups, and R 8 R 9 and R 10 The other two are H; R 13 and R 14 Independently selected from H and C 1-3 alkyl; R 11 Selected from H and =O; R 12 Selected from H, C 1-4 Alkyl and succinimide; and p is 1-4.

13. The method according to any one of claims 1 to 12, further comprising administering an effective amount of one or more additional agents for treating cancer and / or cancer therapies.

14. The method of claim 13, wherein the one or more adjunctive agents for treating cancer are small molecule chemotherapy agents, such as cisplatin, tyrosine kinase inhibitors, glutaminase inhibitors (e.g., glutaminase-1 (GLS1) inhibitors) and / or asparagine synthase (ASNS) inhibitors, and known cancer therapies are, for example, radiotherapy, targeted therapies such as antibody therapy (including anti-PD-1 and / or anti-PD-L1 antibodies), immunotherapy, hormone therapy and / or anti-angiogenic therapy.

15. A pharmaceutical composition comprising one or more compounds of formula (I) or pharmaceutically acceptable salts, solvates, and / or ester prodrugs thereof, and a pharmaceutically acceptable carrier: in R 1 R 2 and R 3 It is OH or H independently, provided that R is present. 1 R 2 and R 3 At least one of them is OH; wherein one or more of the compounds of formula (I) or their pharmaceutically acceptable salts, solvates and / or ester prodrugs are present in the composition in an effective amount to increase antitumor immunity or treat cancer.

16. A pharmaceutical composition comprising one or more compounds of formula (II), (III) or (IV) or their pharmaceutically acceptable salts, solvates and / or ester prodrugs, and a pharmaceutically acceptable carrier: in R 4 Selected from halogens, NR 5 R 6 and C 1-3 Alkyl groups; and R 5 and R 6 Independently selected from H and C 1-3 alkyl; in R 7 It is OH; and n is 3-5; or The compound of one or more of formula (II), (III) or (IV), or a pharmaceutically acceptable salt, solvate and / or ester prodrug thereof, is present in the composition in an effective amount to increase antitumor immunity or treat cancer.

17. The pharmaceutical composition according to claim 15 or 16, for preparing a medicament for treating cancer.

18. The pharmaceutical composition according to claim 17, further comprising one or more additional anticancer agents.

19. The pharmaceutical composition of claim 18, wherein one or more additional anticancer agents are selected from cisplatin, tyrosine kinase inhibitors, glutaminase inhibitors (e.g., glutaminase-1 (GLS1) inhibitors), asparagine synthase (ASNS) inhibitors, immune checkpoint blockers, and antibody therapies (including anti-PD-1 and / or anti-PD-L1 antibodies).

20. The pharmaceutical composition of claim 19, wherein the immune checkpoint blocker is a PD-1 inhibitor or a PD-L1 inhibitor, wherein the PD-1 inhibitor comprises one or more of pembrolizumab, nivolumab, and cimipril, and the PD-L1 inhibitor comprises one or more of atezolizumab, avelumab, and durvalumab.

21. The pharmaceutical composition of claim 19, wherein the immune checkpoint blocker is a CTLA-4 inhibitor, including ipilimumab and / or texilimumab.

22. The pharmaceutical composition of claim 21, wherein the immune checkpoint blocker is a LAG-3 inhibitor, including renalalimab and / or olpdullagra.